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Summary 
Malignant melanoma is the most severe form of skin cancer being refractory to current 
therapies at advanced stages (stage III and IV). The survival of individual patients can vary 
from months to years, but the molecular mechanism behind this broad survival time range is 
unknown so far. Many signaling pathways have been found to be important in melanoma and 
recently microRNAs (miRNAs) have emerged to be essential regulators in these pathways. 
This study aimed at the identification of miRNAs accounting for the aggressiveness of 
melanoma. 
Using bead-based microarray analyses, we performed miRNA expression profiling on a panel 
of melanoma cell lines derived from metastatic melanoma patients with either long or short 
survival times. Upon comparison of these two patient groups a number of differentially 
expressed miRNAs could be identified. However, subsequent real-time quantitative PCR 
(qPCR) revealed that only one candidate miRNA (miR-101) was confirmed to be 
down-regulated in cell lines from short term survivors, compared to long term survivors. 
We found that miR-101 could directly target microphthalmia-associated transcription factor 
(MITF) in melanoma cells, leading to a decrease in intracellular MITF protein expression. One 
of the predicted target sites for miR-101 in the 3’ UTR of MITF was confirmed by luciferase 
reporter assay. Furthermore, we show that the expression of “enhancer of zeste homolog 2” 
(EZH2), previously reported as miR-101 target in other types of cancer, was down-regulated 
by miR-101 also in melanoma. Overexpression of miR-101 inhibited proliferation, invasion 
and migration of melanoma cells, which could be phenocopied by siRNA-mediated 
knockdown of MITF or EZH2 using specific siRNA.  
miR-137 was reported to act as a tumor suppressor in different cancer entities including 
melanoma. In this study, we showed that low miR-137 expression correlated with poor 
survival of stage IV melanoma patients. We identified three novel targets (proto-oncogene 
c-Met, Y box binding protein 1 [YB1] and the ATP-binding cassette, sub-family B, member 5 
[ABCB5]) and confirmed two previously reported targets (MITF and EZH2) for miR-137. 
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Overexpression of miR-137 suppressed invasion of melanoma cells, which could be 
phenocopied by siRNA-mediated knockdown of the miR-137 targets c-Met, YB1, MITF and 
EZH2. Furthermore, miR-137 inhibited melanoma cell migration and proliferation likely 
through the down-regulation of certain proteins (e.g. YB1 and EZH2) whose individual impact 
on these processes varied among the two cell lines tested. Finally, miR-137 induced 
apoptosis in melanoma cell lines and decreased B-cell lymphoma 2 (BCL2) protein 
expression levels. 
In conclusion, our study suggests that miR-101 and miR-137 can function as tumor 
suppressors in melanoma. We show that overexpression of these miRNAs could lower the 
aggressiveness of melanoma cells by regulation of multiple signaling pathways, offering new 
options for targeted therapy against melanoma. 
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Zusammenfassung 
Das Maligne Melanom zeichnet sich im fortgeschrittenen Stadium (Stadium III und IV) durch 
eine ausgeprägte Resistenz gegenüber aktuell angewandten Therapieformen aus und stellt 
somit die schwerwiegendste Form aller Hautkrebsarten dar. Die Überlebensdauer der 
Patienten beträgt zwischen einigen Monaten bis mehren Jahren, allerdings ist der molekulare 
Mechanismus der für diese große Schwankungsbreite verantwortlich ist, noch ungeklärt. 
Bisher konnten etliche Signalkaskaden identifiziert werden, die für das Melanomwachstum 
relevant sind, doch kürzlich wurden microRNAs (miRNAs) als essentielle Regulatoren dieser 
Signalwege ermittelt. Das Ziel der vorliegenden Arbeit bestand in der Identifizierung von 
miRNAs, die zur Aggressivität von Melanomen beitragen. 
Mit Hilfe von „Bead“-basierten Micro-Array-Analysen konnte ein miRNA Profil für eine Reihe 
von Melanom-Linien erstellt werden, die aus Tumorpatienten mit metastasierten Melanomen 
und langer bzw. kurzer Überlebensdauer stammten. Durch den direkten Vergleich dieser 
beiden Patientengruppen konnte eine Reihe von differenziell exprimierten miRNAs 
identifiziert werden. Allerdings konnte in der anschließend durchgeführten quantitative 
Real-Time PCR Analyse nur eine miRNA (miR-101) als eine in Melanom-Linien aus Patienten 
mit kurzer Überlebensdauer spezifisch herabregulierte miRNA bestätigt werden. 
Wir fanden, dass miR-101 auf den „Micropthalmia-assoziierten Transkrpitionsfaktor“ (MITF) 
einwirkt und zu dessen verminderten intrazellulären Proteinexpression führt. Eine der 
vorhergesagten miR-101-Bindungsstellen im in der 3’UTR der MITF-spezifischen mRNA 
konnte mit Hilfe von Luziferase Reporter-Tests bestätigt werden. Darüber hinaus konnten wir 
zeigen, dass das Protein „Enhancer of Zeste Homolog 2“ (EZH2), das bereits in anderen 
Tumorentitäten als Zielstruktur für miR-101 beschrieben wurde, auch in Melanomen durch 
miR101 herab reguliert wird. Durch Überexpression von miR-101 wurden Proliferation, 
Invasion und Migration von Melanomzellen inhibiert, ein Effekt, der auch stellvertretend durch 
die si-RNA-vermittelte Ausschaltung von MITF oder EZH2 erzielt werden konnte. 
miR-137 wurde für verschiedene Tumorarten, einschließlich des Malignen Melanoms, als 
Tumorsuppressor- microRNA beschrieben. In der vorliegenden Arbeit konnten wir zeigen, 
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dass eine niedrige miR-137 Expression mit einer verminderten Überlebensrate von Patienten 
im Stadium IV einher geht. Darüber hinaus wurden drei Proteine identifiziert, deren 
Expression miR-137- abhängig moduliert wird, nämlich das Proto-Onkogen c-Met, das „Y-Box 
Binding Protein 1“ (YB-1) und das „ATP-Binding Cassette, Subfamily B, Member 5“-Protein 
(ABCB5). Die bereits früher beschriebene miR-137-vermittelte Modulation der Expression von 
MITF und EZH2 konnte im Rahmen der vorliegenden Arbeit ebenfalls bestätigt werden. Durch 
Überexpression von miR-137 wurde die Invasion von Melanomzellen inhibiert; dieser Effekt 
konnte durch siRNA-vermittelte Unterdrückung der Expression von c-Met, YB1, MITF und 
EZH2 imitiert werden. Darüber hinaus inhibierte miR-137 durch Herabregulierung bestimmter 
Proteine (u. a. YB1 und EZH2) auch die Migration und Proliferation von Melanomzellen. Die 
targetierten Proteine zeigten hierbei sowohl innerhalb einer Melanomlinie als auch zwischen 
den beiden getesteten Melanomlinien unterschiedlich stark ausgeprägte Effekte. Darüber 
hinaus Des Weiteren löste miR-137 Apoptose in Melanomlinien aus und führte zu einer 
verminderten Expression des „B-Cell-Lymphoma 2“ Proteins (BCL-2). 
Unsere Studie legt die Schlussfolgerung nahe, dass miR-101 und miR-137 als 
Tumor-suppressoren in Melanomen fungieren können. Wir zeigen, dass die Überexpression 
dieser miRNAs die Aggressivität von Melanomzellen durch die Regulation mehrerer 
Signalwege verringern kann. Hierdurch könnten Optionen für neue Therapieansätze gegen 
das Maligne Melanom geschaffen werden. 
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1 INTRODUCTION 
1.1 Melanoma 
Melanoma is the malignant transformation of melanocytes, which mainly reside in the skin 
and eye and produce the dark pigment, melanin. Although melanoma accounts for less than 
5% of all skin cancer cases, it causes more than 70% of all skin cancer deaths (1). Melanoma 
patients diagnosed at early stages can be cured by surgery. However, patients with 
metastasis are usually refractory to current therapeutic strategies and the 5-year survival 
rates for them is only 15% (2).  
1.1.1 Progression of melanoma 
In 1984, Clark et al. proposed a multi-step progression model of melanocyte-to-melanoma 
transformation based on clinical and histopathological observations (Figure 1) (3). This model 
has been widely accepted in the melanoma research community (2, 4). In normal skin, 
melanocytes are evenly distributed in the basal level of the epidermis. The initiation step is the 
proliferation of melanocytes which leads to the benign nevus. The second step is the 
development of the aberrant growth, which may occur in a preexisting nevus or as new nevus, 
resulting in the dysplastic nevus. The next step is the radial-growth phase in which cells are 
able to proliferate intraepidermally. Then, cells may enter the vertical-growth phase during 
which they acquire the capability to invade throughout the dermis and form an expanded 
nodule. Cells isolated from this stage are able to grow in soft agar and form tumor when 
implanted in nude mice. The last step in the model is metastatic melanoma which disseminate 
malignant cells to other location of skin and to other organs through the vascular and 
lymphatic systems. 
1.1.2 Types of melanoma 
Clinically, there are four main types of melanoma (2, 5). Superficial spreading melanoma 
(SSM) is currently the most common form of melanoma, accounting for 70% of cutaneous 
melanoma. It undergoes a radial growth phase in which the lesion is limited to the epidermis. 
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In the later vertical growth phase, the lesion stretches down into the dermis with an increased 
metastatic potential. Nodular melanoma (NM) is the most aggressive type of melanoma. It 
lacks a significant radial growth phase and has a predominantly vertical growth phase. It may 
appear in a place where a previous lesion was not seen. Most of NMs are darkly pigmented; 
however they can also be light or even non-pigmented. Acral lentiginous melanoma (ALM) is 
observed on the palms, soles, under the nails and in the oral mucosa. Unlike other types, 
ALM does not appear to be linked to ultraviolet (UV) exposure. Lentigo maligna melanoma 
(LMM), also called melanoma in situ, usually arises on sun-damaged skin such as face, neck 
and forearms of the elderly. It is the least common and the least aggressive type of cutaneous 
melanoma. The benign precursor of LMM, lentigo maligna, is a flat and large tan macule 
which may grow slowly for 3 to 15 years. Less than 5% of lentigo maligna will undergo vertical 
growth and become LMM eventually.  
 
Figure 1  Biological events in Clark’s model for melanoma progression. Adapted from Miller et al. 2006 (4).  
1.1.3 Staging of melanoma 
Staging is a method of summarizing how far a cancer has progressed based on the physical 
examination, imaging tests, biopsies, and other tests. According to AJCC’s guidelines (6, 7), 
melanoma is grouped into five different stages within which subclasses are further 
categorized. Stage 0 melanoma resides in the epidermis, but has not spread into the dermis. 
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Stage I and Stage II melanoma are characterized by tumor presence, thickness, mitotic rates, 
and ulceration status. There is no evidence of regional lymph node or distant metastasis.  
Stage III melanoma is defined by lymph node metastases and absence of distant metastasis. 
Stage IV melanoma is characterized by distant metastases and the level of serum lactate 
dehydrogenase. At this stage, tumor has spread to other organs such as the liver, lung, or 
brain, to distant areas of the skin, or to distant lymph nodes. The staging system helps doctors 
to determine patients’ prognosis and the appropriate treatments.  
1.1.4 Treatment options for melanoma 
At early stages, most melanoma can be cured by surgical resection. However, when 
metastasis is implicated, the disease becomes very aggressive and treatment may include 
surgery, chemotherapy, radiotherapy or a combination of these methods. Many 
chemotherapy drugs have been used in the treatment for melanoma. Single-agent 
Dacarbazine (DTIC) is the only FDA-approved chemotherapeutic agent for the treatment of 
advanced melanoma, but the response rate is only 10% to 20% and the median response 
duration is 4 to 6 months. Several adjuvant therapies have also been approved for melanoma 
(8). Among them, interferon-α and interleuin-2 are widely used in adjuvant immunotherapy for 
metastatic melanoma, although the response rates are low and toxicity is still a problem (2). In 
addition, large efforts have been made to stimulate tumor-specific T cell response, including 
vaccination using specific tumor antigens (e.g. MLANA, SILV and TYR), adoptive T cell 
transfer and blockage of T cell checkpoint molecules such as cytotoxic T 
lymphocyte–associated protein 4 (CTLA4) and programmed cell death 1 (PDCD1) (9). Some 
of these approaches have shown to be promising, but they are still under clinical investigation.  
Meanwhile, intensive studies have been carried out on crucial molecular signaling pathways 
involved in melanoma, which have started to elucidate the mechanisms behind this disease 
and is opening the possibility of targeted therapy. 
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1.1.5 Important signaling pathways in melanoma 
1.1.5.1 Ras/Raf/MEK/MAPK pathway 
The Ras/Raf/MEK/M pathway (Figure 2), which plays a key regulatory role on melanoma cell 
proliferation and survival, is constitutively active in most melanoma (2, 4, 10). In melanocytes, 
this pathway can be activated by paracrine growth factors such as stem cell factor (SCF), 
hepatocyte growth factor (HGF), and fibroblast growth factor (FGF). In contrast, melanoma 
cells may produce growth factors, such as HGF and FGF, by themselves and regulate this 
signaling pathway in an autocrine manner (11). When activated, the growth factor receptors 
are linked to RAS proteins which then activate RAF proteins that in turn activate MAPK/ERK 
kinase (MEK). MEK acts on mitogen-activated protein kinase (MAPK, also known as ERK) 
which phosphorylates many targets in the cytoplasm and interacts with other pathways, such 
as cell death pathway and MITF pathway. MAPK also translocates into to the nucleus and 
regulates gene expression that promotes proliferation. A more common way to activate this 
pathway is through gain-of-function mutations in NRAS and BRAF genes. Reports have 
shown that NRAS is mutated in 15% to 30% of melanomas and BRAF is mutated in 50% to 
70% of melanomas (12).  
1.1.5.2 PI3K/AKT pathway 
Another important pathway in melanoma is PTEN/PI3K/AKT pathway (Figure 2) which 
regulates cell survival, proliferation and motility (2, 4, 10, 13). Typically, growth factors bind to 
their receptor tyrosine kinases which activate phosphatidylinositol 3 kinase (PI3K), leading to 
the conversion of the plasma membrane lipid phosphatidylinositol (4, 5)-bisphosphate (PIP2) 
to phosphatidylinositol (3, 4, 5)-trisphosphate (PIP3). PIP3 acts as a second messenger 
which phosphorylates v-akt murine thymoma viral oncogene homolog (AKT), and in turn, a 
number of mitogenic processes are activated including inhibition of apoptosis, survival gene 
transcription, cell cycle progression, protein translation, and proliferation. This pathway is 
terminated by phosphatase and tensin homologue (PTEN) through dephosphorylation of PIP3. 
PTEN mutations have been found in 30% - 50% of melanoma cell lines (13, 14) and PTEN 
protein levels are low or absent in melanoma (15, 16).  
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Figure 2  Ras/Raf/MEK/MAPK and PI3K/AKT pathway. VEGF, vascular endothelial growth factor; SCF, stem 
cell factor; HGF, hepatocyte growth factor; FGF, fibroblast growth factor; c-KIT, v-kit Hardy-Zuckerman 4 feline 
sarcomaviral oncogene homolog; IGF, insulin-like growth factor; IGFBP, IGF binding protein; P, phosphate; SHC, 
Src homology 2 domain– containing protein; c-FOS, v-fos FBJ murine osteosarcoma viral oncogene homolog; 
ELK1, member of ETS oncogene family;PI, phosphatidylinositol; PI3K, phosphatidylinositol 3 kinase; AKT, v-akt 
murine thymoma viral oncogene homolog; PDK1, phosphoinositide-dependent kinase 1; mTOR, mammalian target 
of rapamycin; CCND1, cyclin D1; FOXO1, forkhead box O1. Adapted from Sekulic et al. (10).  
1.1.5.3 MITF and β-catenin pathways 
MITF is a basic helix–loop–helix leucine zipper dimeric transcription factor, which is the 
master regulator of melanocyte development and differentiation, and also a key player in 
melanoma (17). Several pathways regulate MITF expression transcriptionally through the 
promoter (Figure 3). The crucial ones are the melanocortin and β-catenin pathways (4, 10). 
The alpha melanocyte stimulating hormone (α-MSH) binds to the G protein-coupled 
melanocortin receptor 1(MC1R), which activate cAMP response-element binding protein 1 
(CREB1) through adenylate cyclase. CREB1 binds to MITF promoter and activates the 
transcription of MITF. Several growth factors such as KIT and HGF activate the MAPK 
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pathway which mediates the phosphorylation of MITF. Active MITF stimulates the 
transcription of its downstream targets, including genes involved in melanin synthesis (TYR, 
TYRP1, and DCT), genes important for survival (BCL2), and a number of melanoma markers 
(MLANA, SILV, and TRPM1). In the β-catenin pathway, WNT protein binds to the frizzled 
family receptor to inactivate the kinase GSK3B which phosphorylates β-catenin and targets it 
for degradation in the proteosome. Thus, WNT signaling results in increased β-catenin levels, 
which may translocate into the nucleus where it activates the transcription of target genes 
including MITF, CCND1 and matrix metalloproteinase 7 (MMP7). 
 
Figure 3  Cooperation of MITF and β-catenin pathways.  α-MSH, alpha melanocyte stimulating hormone; 
PAX3, paired box 3; SOX10, sex-determining region Y–box 10;CREB1, cAMP response-element binding protein 1; 
TCF, T-cell factor; LEF, lymphoid enhancer–binding factor; GSK3B, glycogen synthase kinase 3 beta; TYR, 
tyrosinase; TRYP1, tyrosinase-related protein 1; DCT, dopachrome tautomerase; MLANA, melan-A; SILV, silver 
homolog (mouse); EDN, endothelin; P, phosphate. Adapted from Sekulic et al. (10). 
In addition to the above-mentioned pathways, many others also play important roles in the 
development and progression of melanoma. These pathways often interact with one another 
and thereby form highly complex signaling networks. Enormous efforts have been made to 
unravel the molecular mechanisms behind this disease. Over the past decade, a new group of 
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molecules, miRNAs, have emerged to be essential and powerful regulators in most biological 
processes in cancers, including melanoma (18). 
1.2 miRNA 
miRNAs are a large family of short (~22 nucleotides [nt]), endogenous and single-stranded 
RNA molecules that regulate gene expression posttranscriptionally (19, 20). In human, 
miRNAs are predicted to target at least 30% of all protein coding genes (21). Functional 
studies show that miRNAs participate in the regulation of mostly every cellular process 
investigated so far and they are involved in many human diseases (22).  
1.2.1 Biogenesis of miRNAs 
As shown in Figure 4, primary miRNA (pri-miRNA) is transcribed from an independent gene 
or from an intron of protein-coding gene by RNA polymerase II (RNAPII) in the nucleus (23). A 
member of RNase III family, Drosha, and a double-stranded RNA binding protein, DGCR8, 
form a complex that process pri-miRNA into a ~70-nucleotide hairpin precursor (pre-miRNA), 
which is exported to the cytoplasm by Exportin 5 in a Ran-GTP manner. Some pre-miRNAs 
are processed from short introns (mirtrons) due to splicing and debranching, therefore 
bypassing the Drosha-DGCR8 step. In either case, pre-miRNA is cleaved by another RNase 
III enzyme, Dicer, with the assistance of RNA binding protein TRBP to form a ~70 bp 
miRNA/miRNA* duplex. In mammal,  the 3’ arm of some pre-miRNAs with high degree of 
complementarity along the hairpin stem is cleaved by Argonaute 2 (AGO2) before 
Dicer-mediated cleavage, thus forming an additional intermediate called AGO2-cleaved 
precursor miRNA (ac-pre-miRNA), which facilitates subsequent strand dissociation (24). Then, 
one strand of the miRNA/miRNA* duplex (guide strand) is preferentially loaded into an 
miRNA-induced silencing complex (miRISC), while the other strand (passenger strand or 
miRNA*) is released and degraded. Not all miRNA* are only byproducts and sometimes both 
strand can be functional. Based on complementarity, miRNA guides the miRISC to the target 
mRNA, leading to translational repression, mRNA deadenylation, or degradation.  
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Figure 4  miRNA biogenesis.  RNAPII, RNA polymerase II; DGCR8, DiGeorge syndrome critical region gene 8; 
GW182, glycine-tryptophan protein of 182 kDa; m7G, 7-methylguanosine-cap; PABP, poly(A) binding protein, 
miRISC, miRNA-induced silencing complex; ac-pre-miRNA, AGO2-cleaved precursor miRNA. Adapted from Krol 
et al. (22) 
1.2.2 Identification of miRNA targets 
Identification of miRNA targets is the key to understand the functions of miRNAs. To this end, 
several approaches have been invented to screen and to validate miRNA targets (25).  
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1.2.2.1 Computational prediction of miRNA targets 
Basic principles of miRNA target prediction 
miRNAs regulate gene expression through binding to the mRNA of their targets. Although the 
mechanism of targeting is not totally elucidated so far, some important features have emerged 
on target recognition, which have become the basis of the current prediction algorithms (20).  
Bioinformatic analysis of the first known miRNA-mRNA interaction showed that 
complementarity of miRNA seed region (position: 5’ nucleotides 2-8 ) to the 3′ UTR of the 
target mRNA is often important, and this commonly accepted principle have been applied in 
almost all currently used algorisms (20). Other criteria that are used in target predictions 
include evolutionary conservation of target site, free energy of the miRNA-mRNA 
heteroduplex, and mRNA sequence features surrounding the target site (25). Current 
prediction algorithms put different weight on these parameters.  
Examples of prediction algorithms 
TargetScan (26) and PicTar (21) are among the most commonly used algorithms. Both of 
them require stringent seed pairing although the impact of the target nucleotide opposite to 
the first miRNA nucleotide are different, and both take into account the conservation of target 
sites which improves their prediction (21, 26-28). TargetScan also considers features in the 
surrounding sequences of target sites, summed as “context score” in the output of the 
program, which improves the prediction for non-conserved target sites (29). The miRanda (30) 
algorithm requires moderately stringent seed pairing and allows G∙U wobbles, which is more 
sensitive in predicting imperfect seed-pairing target sites, and also uses free energy of 
miRNA-mRNA heteroduplex and evolutionary conservation as criteria (31). 
Some other algorithms are generated based on the notion that target site accessibility is 
critical in miRNA-mRNA interaction (32, 33). Those algorithms consider not only the free 
energy of miRNA-mRNA heteroduplex, but also the free energy required to unfold the 
secondary structure surrounding the target site (25). One example is the PITA algorithm, 
which calculates the combined interaction energy (ΔΔG) based on the miRNA-mRNA 
hybridization energy (ΔGduplex) and the energy cost to make the target site accessible 
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(ΔGopen) (32). PITA calculates ΔΔG for seed match irrespective of conservation and 
searching for target sites outside the 3’ UTR is possible. 
Limitations of miRNA target prediction 
Although computational methods are strong tools to suggest putative miRNA targets, they are 
still not satisfactory due to the fact that the mechanisms of miRNA function is not fully 
understood. A prediction algorithm often offers a list of hundreds of candidate targets for a 
single miRNA. The lists of predicted targets generated by different algorithms often have 
limited overlaps (20, 34), which may be attributed to several reasons. First, the seed-pairing 
rules applied to predict targets vary in different algorithms. For instance, TargetScan rewards 
an A on position 1, whereas the other algorithm with stringent seed pairing reward a 
Watson–Crick match on this position (20). Second, the ranking methods are different across 
those algorithms. Third, some algorithms use different 3’ UTR databases. For example, 
Targetscan uses the NCBI Reference Sequence (RefSeq) to define 3’-UTRs for human genes 
(29, 35), whereas miRanda uses the University of California Santa Cruz (UCSC) database 
(31, 36).  Multiple lines of evidence suggest that in addition to 3’ UTR, miRNA can also 
regulate gene expression through binding to the 5’ UTR or the coding region of mRNA (37-40). 
However, most commonly used prediction tools, such as TargetScan, Pictar, and miRanda, 
do not predict target sites outside 3’ UTR. Moreover, 3’ pairing of the miRNA can supplement 
seed pairing to enhance target recognition, or in some cases it can even compensate for a 
mismatch in the seed (20), which raises more challenges for target prediction. Therefore, 
experimentally screening and validation of miRNA targets are essential in miRNA research. 
1.2.2.2 Experimentally identification of miRNA targets 
Microarray based Transcriptome analyses 
The discovery that miRNAs can down-regulate the mRNA level of their targets paved the road 
for a number of subsequent studies (41, 42) in which overexpression and/or inhibition of a 
individual miRNA followed by transcriptome-wide microarray analysis was applied to identify 
candidate miRNA targets (28, 43, 44). In the initial study conducted by Lim et al., the 
brain-specific miR-124 or muscle-specific miR-1 was individually transfected into HeLa cells 
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and microarray analysis was performed for the transfectants (41). In each case, the miRNA 
shifted the mRNA expression profile towards that of its original tissue. About 100 mRNAs 
were downregulated and the 3' UTR of these mRNAs had a significant propensity to pair to 
the 5' region of the miRNA (41). This pioneer study prompted other groups to use similar 
methods to investigate miRNA targets and functions. To reduce off-targetting effects from 
miRNA overexpression, some studies used complementary oligonucleotides to specifically 
inhibit the miRNA and searched for up-regulated mRNAs (43, 44). Nicolas et al. applied both 
overexpression and inhibition of a miR-149 to narrow down the list of putative miRNA targets 
(45). They found only 49 overlapping mRNAs out of hundreds of mRNAs that were affected by 
either treatment. Twenty-one of the 49 mRNAs contained complementary sequences to 
miR-149 seed, and interestingly, none of them were predicted by the commonly used target 
prediction algorithms, indicating a significant false negative prediction by these algorithms.  
While these methods are successful in identifying a number of miRNA targets, they may fail to 
identify targets that do not undergo mRNA degradation. The microarray analysis itself cannot 
distinguish between direct targeting and indirect effect, thus bioinformatic approaches are 
often applied to facilitate target identification. Nevertheless, putative targets should be 
validated by other experiments. 
Proteomic approaches 
Proteomic approaches are attractive because they are capable of identifying targets regulated 
both by transcript destabilization and by translational inhibition. A well-known technology is 
stable isotope labeling by amino acids in cell culture (SLIAC). In this method, cells with or 
without miRNA treatment are cultured in medium containing heavy or light isotopes of 
essential amino acids typically arginine and lysine, and then the two populations of cells are 
1:1 pooled followed by mass spectrometry analysis to identify and quantify proteins that were 
synthesized with heavy or light amino acids. Thereby, proteins that are regulated during 
treatment of miRNA can be identified (46). Vinther et al. reported the first study to utilize 
SILAC for miRNA target identification. They found 12 out of 504 identified proteins were 
repressed by miR-1 overexpression in HeLa cells and 8 out of the 12 genes contain miR-1 
seed sequences, which is a significant enrichment to the non-regulated genes (46). Following 
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this study, two large-scale studies using SALIC to identify miRNA targets were carried out (33, 
47). Baek et al. deleted mir-223 in mouse neutrophils and identified affected proteins (33). 
Selbach et al. pulse-labeled HeLa cells with isotopes to identify newly synthesized proteins 
that were regulated by miRNAs in HeLa cells (47). Both studies demonstrated that a single 
miRNA could affect the expression of hundreds of proteins. However, proteomic methods 
cannot distinguish between direct and indirect targets.  
Immunoprecipitation of miRISC components 
miRISC is the place where miRNAs bind to their target mRNA and execute their function with 
the assistance of other proteins, such as Agonaute proteins. Approaches have been 
developed to isolate the components of miRISC and identify miRNA targets.  
Several studies have identified miRNA targets by immunoprecipitation of miRISCs containing 
either tagged or endogenous agonaute proteins (48, 49). However, pull-down experiments 
using miRISC proteins do not specify mRNAs to a particular miRNA. To overcome this 
problem, an approach using tagged miRNA to specifically pull down the target mRNAs was 
developed by Orom and Lund recently (50). Generally, synthetic miRNA duplex is labeled with 
biotin at the 3’ end of the guide strand and transfected into cells, where the guide strand is 
loaded into the miRISC and binds to the target mRNA (50). The miRNA-mRNA complexes are 
captured by streptavidin beads and mRNAs can be purified and analyzed (50). However, it is 
not clear whether the biotin tag can have an effect on the binding of miRNA and mRNA.  
Recently a new technique called high-throughput sequencing of RNAs isolated by 
crosslinking immunoprecipitation (HITS-CLIP), has been developed, which utilize UV 
irradiation to crosslink RNA and RNA-binding proteins prior to immunoprecipitation, followed 
by deep sequencing to comprehensively identify the bound RNAs (51). HITS-CLIP is powerful 
in finding the potential targets mRNAs for miRNAs. However, there are two major 
disadvantages: the efficiency of UV 254 nm RNA-protein crosslinking is usually low, and the 
location of the crosslink is not readily identifiable within the sequenced crosslinked fragments 
(52). To overcome these disadvantages, Hafner et al. improved the method by treating the 
cell with a photoactivatable nucleoside analog 4-thiouridine which could substitute thymidine 
in transcription and subsequentially increase the crosslinking efficiency (53). This method is 
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termed as photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation 
(PAR-CLIP). The more attracting feature of PAR-CLIP is that there is a prominent transition 
from thymidine (T) to cytidine (C) in the crosslinked sites during cDNA synthesis from the 
isolated RNA fragments. This allows the method to map target sites more precisely. 
Validation of putative miRNA targets 
Identification of putative miRNA targets using the above-mentioned methods is only the first 
step. The next step is to specifically validate whether a putative target is a bona fide direct 
target of a miRNA (25, 34). Usually, qPCR and Western blotting are performed to examine the 
effect of miRNA (overexpression or knockdown) on the mRNA and protein levels of a target 
gene. Direct targeting is confirmed by reporter assay in which the expression of a reporter 
plasmid containing full-length or a fragment of the 3’ UTR is regulated by miRNA. Specific 
target site can be identified by introduction of mutation or deletion in the putative target site in 
the reporter assay. 
1.2.3 miRNA and cancer 
The first study that links miRNA to cancer showed frequent down-regulation or deletion of 
miR-15a and miR-16 most chronic lymphocytic leukemia (CLL) patients (54). Since then, 
miRNA expression profiling and functional studies of miRNAs in cancer have been growing 
exponentially, which demonstrate that miRNAs are important players in cancer development 
and progression. 
1.2.3.1 miRNA expression profiling in cancer 
In 2005, Jiang et al. used a qPCR method to examine the expression of 222 miRNA 
precursors in 32 human cell lines from lung, breast, colorectal, hematologic, prostate, 
pancreatic, and head and neck cancers, and they found that the cell lines could be grouped 
on the basis of their tissue origins using hierarchical clustering analysis (55). Lu et al. used a 
bead-based flow cytometric miRNA expression profiling method to analyze 217 miRNAs from 
334 samples of multiple human cancers. The resulting miRNA profiles reflected the 
developmental lineage and differentiation state of  the tumors, which showed the potential of 
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miRNA profiling in cancer diagnosis (56). In another study, Volinia et al. carried out a 
large-scale microarray analysis of 228 miRNAs in 540 samples including different types of 
cancer and normal controls (57). They identified a cancer miRNA signature composed by a 
large portion of overexpressed miRNAs and some of them had shown well characterized 
cancer association (57). Moreover, many predicted targets of these differentially expressed 
miRNAs are oncogenes or tumor suppressors including Retinoblastoma 1 (RB1) and 
transforming growth factor, beta receptor II (TGFBR2), which were further validated 
experimentally (57). The investigations on miRNA profiling paved the way for the later more 
extensive studies on the functions of miRNAs in cancer. 
1.2.3.2 Functions of miRNA in cancer 
Cancer cells display dysregulated miRNA expression profiles compared to their normal 
counterparts. Studies have shown that miRNAs can act as either oncogenes or tumor 
suppressors depending on their downstream target genes (tumor suppressors or oncogenes) 
(58) . 
miRNA as oncogene 
A number of miRNAs have been found to be oncogenic. In the miRNA profiling study carried 
out by Volinia et al., 21 differentially expressed miRNAs were found in at least three different 
cancers, and on the top of the list was miR-21, which was overexpressed in 6 types of cancer, 
including breast, colon, lung, pancreas, prostate and stomach cancer (57). miR-21 was also 
shown to be overexpressed in cholangiocarcinomas, and directly target the tumor suppressor 
PTEN, whose function is altered in various advanced cancers. Other studies have shown that 
miR-21 can target the pro-apoptotic factor PDCD4 and the tumor suppressor gene 
tropomyosin 1 (TPM1) in breast cancer (59, 60), and miR-21 expression can be induced by 
AP-1 (c-Jun/c-Fos heterodimer) transcription factor which in turn inhibits expression of PTEN 
and PDCD4 (61).  
There is a cluster of miRNAs, miR-17-92 cluster, the members of which are known to act as 
oncogenes promoting cell proliferation, suppressing apoptosis, and inducing tumor 
angiogenesis (62). The miR-17-92 cluster is up-regulated in both hematopoietic malignancies 
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and solid tumors (57, 63, 64). In a human B-cell line, overexpression of c-Myc induced the 
expression of the miR-17-92 cluster that in turn inhibits the expression of E2F1, which is also 
a target of c-Myc and induces apoptosis at high level (65). Thus, c-Myc promotes E2F1 
transcription and in parallel limits the translation, allowing a tightly controlled proliferative 
signaling (65). The miR-17-92 cluster can inhibit the expression of the anti-angiogenic factor 
thrombospondin-1 (TSP1) and the connective tissue growth factor (CTGF), thereby promoting 
tumor angiogenesis (66).  
A number of other oncogenic miRNAs have been shown to play essential roles in cancer, 
such as miR-200c which targets zincfinger E-box binding homeobox 1 (ZEB1) and facilitates 
epithelial-mesenchymal transition (EMT) in various cancers (67), miR-10b which promotes 
tumor invasion and metastasis in breast cancer (68), and miR-146b-5p which contributes to 
thyroid tumorigenesis (69). 
miRNA as tumor suppressor 
Meanwhile, a lot of miRNAs have been shown to be tumor suppressors. The observation that 
the 13q14 region is frequently deleted in the CLLs suggested the existence of a tumor 
suppressor gene in that locus (54). For a long time, scientists had been searching for a 
candidate tumor suppressor in this region, but did not identify a suitable protein-coding gene. 
Calin et al. discovered that miR-15a and miR-16-1 are located in the first intron of a 
non-coding gene called leukemia associated gene 2 (LEU2), which is in the minimally deleted 
region in the CLLs (70). miR-15a and miR-16 are both deleted or down-regulated in the 
majority of CLL patients. Further studies from the same laboratory showed that both miRNAs 
could down-regulate BCL2 expression posttranscriptionally and induce apoptosis in a 
leukemic cell line model (71). The miR-15a/miR-16-1 deletion was also found in other cancers, 
such as prostate, breast, ovary, and bladder cancers (72). Another study in prostate cancer 
showed that miR-15a and miR-16 target CCND1 and WNT3A, which promotes cell survival, 
proliferation and invasion (73). These findings suggest that miR-15a and miR-16 are bona fide 
tumor suppressors.  
The let-7 family is among the most actively studied tumor suppressive miRNAs. It has been 
shown that the let-7 family is down-regulated in different cancers such as lung cancer(74), 
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ovarian cancer (75), and colon cancer (76). Takamizawa et al. found that reduced expression 
of let-7 in human lung cancers was associated with poor postoperative survival (77). Johnson 
et al. showed for the first time that let-7 could target all three human RAS genes (HRAS, 
KRAS and NRAS) (74), and in another report they found overexpression of let-7 in cancer cell 
lines altered cell cycle progression and inhibited cell division by targeting multiple genes, 
which suggested that let-7 could be a master regulator of cell proliferation pathway (78). Akao 
et al. reported that let-7 inhibited protein expression of RAS and c-MYC in colon cancer cells 
and thereby significantly suppressed cell growth (76). Lee et al. found that let-7 repressed 
expression of the HMGA2 oncogene (79). 
In 2007, reports from several research groups showed that members of miR-34 family are 
direct transcriptional targets of p53 tumor suppressor, which connected the p53 pathway with 
miRNA network for the first time (80-83).  Ectopic miR-34 expression induces apoptosis and 
promotes cell-cycle arrest, while loss of miR-34 can impair p53-mediated cell death (84). 
Dozens of miR-34 Targets have been identified and many of them are regulators of cell cycle, 
apoptosis, proliferation, migration and invasion, including c-MYC, E2F3, BCL2, CDK4, CDK6 
and c-Met (85). miR-34 expression can be inactivated by promoter hypermethylation  in 
various types of cancer (86). 
Another notable tumor suppressive miRNA is miR-101. Varambally et al. reported that the 
genomic locus encoding miR-101 was lost in 37.5% of clinically localized prostate cancer 
tissues and 66.7% of metastatic tissues (87). The copy number alteration caused a decrease 
of miR-101 expression during cancer progression paralleled by an increase of EZH2 
expression. miR-101 could directly target EZH2 leading to inhibition of cell proliferation, 
invasion and tumor growth. This targeting was confirmed in different cancers, including 
bladder transitional cell carcinoma (88), gastric cancer (89), glioblastoma (90) and non-small 
cell lung cancer (NSCLC) (91). Further studies showed that miR-101 could target multiple 
oncogenes, including myeloid cell leukemia sequence 1 (MCL1) in hepatocellular carcinoma 
(92), cyclooxygenase-2 (COX2) in colon cancer (93), and MYCN in neuroblastoma (94). 
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1.2.3.3 miRNAs in melanoma 
miRNA profiling in melanoma 
The earliest publication concerning miRNAs in melanoma dates back to 2005 when Lu et al. 
utilized a bead-based miRNA profiling method to analyzed 217 miRNAs from 334 samples 
including several types of tumor tissues and normal tissues (56). In this pioneer study, they 
found that miRNA profiles were able to classify tumors based on the developmental lineage 
and differentiation state. There was a general down-regulation of miRNAs in tumor samples 
compared to normal samples. However, among the large set of samples, there were only 
three melanoma tissue samples and two melanoma cell lines, which were not grouped 
together in the clustering analysis. Duo to the lack of normal melanocyte controls, comparison 
of miRNA expression between melanoma and normal melanocytes were not possible from 
their data.  
In the next two years, more melanoma cell lines were included in three studies which 
analyzed miRNA copy number or expression in panels of different tumor tissues and cell lines 
(95-97). In 2006, Zhang et al. evaluated genome-wide miRNA DNA copy number 
abnormalities in 227 human ovarian cancer, breast cancer, and melanoma specimens (95). 
They found that 85.9% (243 of 283) of miRNA genes were located in regions that exhibited 
DNA copy number abnormalities in melanoma and some of them were specific in this cancer. 
They confirmed that the miRNA expression was correlated with the copy number of the 
respective miRNA, which indicated that copy number changes of miRNA genes may account 
for dysegulation of miRNA.  
In 2007, Gaur et al. analyzed the expression of 241 miRNAs in normal tissues and a panel of 
fifty-nine NCI-60 cell lines derived from hematologic, colon, central nervous system, and 
melanoma tumor (96). The tumor cell lines were clustered in a way that reflected their tissue 
origin. Fifteen miRNAs (4 up- and 11 down-regulated) were found to be differentially 
expressed in the eight melanoma cell lines compared to the other cancer cell lines. However, 
in contrast to the other tumor types, comparison between melanoma and healthy tissue was 
not performed, because there was no suitable control for melanoma in the panel of normal 
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tissues used in this study. In another study, Blower et al. also performed miRNA profiling for 
the NCI-60 cell lines and found cell lines from the same origin were clustered together (97). 
By comparing miRNA expression patterns with compound potency patterns, they suggest that 
miRNAs may play a role in chemo-resistance. 
In 2009, Mueller et al. reported the first comprehensive miRNA expression profiling in human 
normal epidermal melanocytes (NHEMs) and well-characterized melanoma cell lines derived 
from primary and metastatic tumors (98). They identified 91 differentially expressed miRNAs 
in primary melanoma cell lines compared to melanocytes, as well as 15 differentially 
expressed miRNAs in metastatic cell lines compared to primary cell lines and melanocytes. In 
both comparisons, most of the differentially expressed miRNAs showed up-regulation. 
Comparison between highly invasive and weakly invasive cell lines revealed 33 differentially 
expressed miRNAs. Expressions of several candidate miRNAs were confirmed by qPCR in 
these cell lines as well as in tissue samples. Thus, this study identified miRNAs that might be 
dysregulated in different steps of melanoma progression such as early progression, invasion 
and metastasis.  
Following the study of Mueller et al., several groups reported their studies on miRNA profiling 
in melanoma from different aspects. Jukic et al. identified miRNAs that were differentially 
expressed between old patients and young patients and these miRNAs were associated with 
cell growth, differentiation, migration, invasion, and EMT (99). Segura et al. identified a 
signature of 18 miRNAs whose overexpression was significantly correlated with 
post-recurrence survival, and a signature of 6 miRNAs which could classify stage III patients 
into better and worse prognostic categories (100). In a comprehensive study carried out by 
Philippidou et al. (101), miRNA expression profiles for NHEMs and melanoma cell lines were 
generated using miRNA microarray, real-time miRNA reverse transcription-PCR array, 
followed by qPCR validation. Tissue samples including benign nevi, primary tumors and 
metastatic tumors were also analyzed in order to correlate with the expression pattern of cell 
lines. Discrepancies were found between different detection techniques and also between 
tissue samples and cell lines. miR-200c was the only miRNA that was commonly 
down-regulated in melanoma cell lines and tumor tissues robustly detected by the three 
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different platforms. Subsequently, whole-genome cDNA array was performed on selected 
melanoma cell lines and melanocytes to identify possible targets of some dysregulated 
miRNAs and bioinformatic analysis identified a dysregulated gene network centered on MITF, 
a key regulator in melanocyte differentiation and melanoma development. 
Although microarray approaches are widely used in miRNA expression profiling, they are 
limited to the analysis of known miRNA species. Deep-sequencing is a more advanced 
technology that is able to identify and quantify not only known miRNAs but also novel miRNAs.  
Stark et al. deep-sequenced 12 small RNA libraries from melanoblasts, melanocytes, 
congenital nevocytes as well as acral, mucosal, cutaneous and uveal melanoma cells (102). 
They identified 539 known mature miRNAs along with the prediction of 279 novel miRNA. 
Their data suggested that some of the potential novel miRNAs were likely to be specific to the 
melanocytic lineage and might become interesting candidates in melanoma research. 
Functions of miRNA in melanoma 
Bemis et al. reported the first functional study of a single miRNA in melanoma (103). They 
found that mir-137 gene is located in the chromosomal region 1p22 known to be associated 
with melanoma susceptibility and computational algorism predicted MITF as a putative target 
of miR-137, which was then validated by experiments. Interestingly, they identified a 15-bp 
variable nucleotide tandem repeat in the 5’ pri-mir-137 sequence, which could affect the 
processing of pri-mir-137 into the mature form and thereby alter its function in melanoma cell 
lines. Moreover, they found that miR-137 expression was decreased by α-MSH, suggesting 
that miR-137 might be involved in sun tanning response. After the first report, studies on 
miRNA functions in melanoma have increased rapidly. 
The let-7 family has been identified to act as tumor suppressor through targeting important 
oncogenes, such as RAS and c-Myc, in various types of cancer (104). The tumor suppressive 
function was also observed in melanoma. Schultz et al. identified 72 differentially expressed 
miRNAs by miRNA expression profiling in benign melanocytic nevi and primary malignant 
melanomas (105). Among them, let-7b was significantly down-regulated in melanoma 
compared with nevi. Overexpression of let-7b in melanoma cells decreased the expression of 
several cell cycle molecules such as cyclins D1, D3, and A, and CDK 4. In particular, cyclin 
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D1 was validated as a direct target of let-7b using reporter assays. Overexpression of let-7b 
inhibited cell cycle progression and anchorage-independent growth of melanoma cells. In 
another study, Mueller et al. found that let-7a was down-regulated in melanoma cell lines 
compared to melanocytes and the expression of integrin β3 showed the opposite pattern 
(106). Integrin β3promotes the migration and invasion of melanoma cells and is involved in 
melanoma progression. Sequence analysis suggested a putative target site for let-7a in the 3’ 
UTR of integrin β3 which was validated by reporter assay. Overexpression of let-7a 
decreased integrin β3 mRNA and protein, and reduced the invasive potential of melanoma 
cells; while inhibition of let-7b increased the invasion of melanocytes. These studies 
demonstrated that loss of let-7 family members may contribute to melanoma development 
and progression through activating various oncogenic processes including pathways acting 
on proliferation, migration and invasion. 
miR-221 and miR-222 are clustered on the X chromosome and are likely transcribed as a 
common precursor (107). They were found to be overexpressed in different cancers including 
pancreatic cancer (108), papillary thyroid carcinoma (109), glioblastoma (110), and prostate 
cancer (111). miR-221/211 were reported to target c-KIT in papillary thyroid carcinoma (109) 
and erythroleukemic cells (112). The receptor tyrosine kinase c-KIT was found to decrease 
with melanoma progression (113, 114). Based on these previous findings, Felicetti et al. 
analyzed the expression of miR-221/222 and c-KIT in melanocytes and melanoma cell lines 
including primary vertical growth phase and metastatic melanomas. They found that 
miR-221/222 expression was increased with tumor progression and was reversely correlated 
with c-KIT expression. They identified the promyelocytic leukemia zinc finger (PLZF) 
transcription factor as a repressor of miR-221/222 by binding to regulatory region of their gene. 
They proposed that down-regulation of PLZF in melanoma cells unblocks miR-221/222 which 
in turn represses the expression of cyclin-dependent kinase inhibitor 1B (CDKN1B) and c-KIT, 
leading to an increase of proliferation and an inhibition of differentiation, respectively. Further 
in vivo experiment showed that overexpression of miR-221/222 promoted tumor growth while 
inhibition of miR-221/222 by antagomir suppressed tumor growth. 
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In the paper from Bemis et al., they suggested that, in addition to miR-137, there might be 
other miRNAs regulating MITF (103). This was proven by the study from Segura et al. who 
reported that miR-182 targets MITF directly (115). miR-182 is located in a chromosomal 
region (7q31-34) frequently amplified in melanoma and is up-regulated in melanoma cell lines 
and tissues. Overexpression of miR-182 increased the migratory activity of melanoma cells in 
vitro and their metastatic potential in vivo. Silencing of miR-182 induced melanoma cell 
apoptosis and impaired their invasive capacity in vitro. Forkhead box O3 (FOXO3) and MITF 
are miR-182 targets and mediators of miR-182 function. Considering the complexity of MITF 
regulation and the long 3’ UTR of MITF, the interplay between miR-137 and miR-182, and 
possibly other miRNAs may contribute to the fine tuning of this important transcription factor.  
In most of the above-mentioned studies, miRNA expression profiling analyses were 
performed first to screen for dysregulated miRNA candidates, followed by target identification 
and functional study. However, profiling data differ substantially between various studies 
using different platforms and samples (101). Thus, it is difficult to unravel miRNA networks for 
functions of interest like invasion and migration, as uncertain expression data would have to 
be combined with uncertain target predictions. In order to obtain candidate miRNAs relevant 
for defined functions, functional screenings using miRNA libraries have been applied in 
various types of cancer including lung (116), breast (117), colorectal (118), pancreatic cancer 
(119), and also for melanoma (120). Levy et al. performed a miRNA library screening in 
A375M melanoma cell line using matrigel invasion assay, and they found that overexpression 
of miR-211 led to the most significant reduction of cell invasion (120). miR-211 is an intronic 
miRNA in the TRPM1 gene which is down-regulated in metastatic melanoma and is thought to 
function as a melanoma tumor suppressor. Further experiments of the group showed a 
decreased expression of miR-211 along with its host gene TRPM1. Increased expression of 
miR-211, but not TRPM1, reduced the migration and invasion of highly invasive melanoma 
cells with low levels of miR-211 and TRPM1. Using gene network analysis, they identified 
three central node genes (insulin-like growth factor 2 receptor [IGF2R], transforming growth 
factor, beta receptor II [TGFBR2] and nuclear factor of activated T-cells 5 [NFAT5]) which 
were validated as miR-211 targets. Knockdown of each target gene phenocopied the effects 
of miR-211 overexpression on melanoma invasiveness. This study proposed that miR-211 
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acts as a tumor suppressor whose expression might be blocked via suppression of the 
TRPM1 locus during melanoma progression. This notion was further confirmed by another 
study reported by Mazar et al. (121) in the same month. Their data showed that miR-211 
could inhibit both proliferation and invasion of melanoma cells, and they identified KCNMA1 
(potassium large conductance calcium-activated channel, subfamily M, alpha member 1) as a 
target of miR-211.  
miRNA expression can be regulated by different mechanisms: alteration of the miRNA 
biogenesis machinery, chromosomal abnormalities, mutations, polymorphisms and epigenetic 
regulation (122). Weber et al. analyzed the genomic sequences of 332 miRNAs in the 
miRBase (Version 8.0) and found that 155 of them (47%) were associated with CpG islands, 
indicating possible epigenetic modulations for these miRNAs (123). Several lines of evidence 
have proven that cancer cells can down-regulate tumor suppressive miRNAs by 
hypermethylation of their promoter regions (124-127). Recently, Perera’s group has made 
efforts on identifying epigenetically regulated miRNAs in melanoma (128, 129). By treating 
melanoma cells with DNA methyltransferase inhibitor 5-aza-2’-deoxycytidine, they found a list 
of up-regulated miRNAs and miR-375 and miR-34b were among the ones that had the 
strongest effects. Further analysis showed that the CpG islands up-stream of miR-375 and 
miR-34b genes were unmethylated or poorly methylated in keratinocytes and melanocytes, 
whereas the methylation of these CpG islands was increased with the stage in melanoma cell 
lines. Both miR-375 and miR-34b were able to inhibit the proliferation, invasion and migration 
of melanoma cells. Their studies suggested that miR-375 and miR-34b might be silenced by 
hypermethylation leading to the impairment of their tumor suppressive functions during the 
progression of melanoma. 
miRNAs as prognostic markers in melanoma 
Since miRNAs are important regulators of many cellular processes which affect the 
aggressiveness of melanoma, they may also serve as prognostic markers for melanoma 
patients like the protein coding genes do. As mentioned above, Segura et al. analyzed 59 
formalin-fixed paraffin-embedded (FFPE) melanoma metastatic samples using miRNA arrays 
containing 911 probes. They identified a signature of 18 miRNAs whose overexpression was 
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significantly correlated with longer post-recurrence survival (>18 months), and a signature of 6 
miRNAs which could categorize stage III patients into better and worse prognostic groups 
(100). Satzger and colleagues tested miR-15b expression in 128 FFPE primary melanoma 
samples and found that high expression of miR-15b was significantly associated with poor 
overall and recurrence free survival (130). Caramuta et al. reported that low expression of 
miR-191 and high expression of miR-193b were associated with poor survival in their data set 
composed of 16 regional lymph node metastatic samples (131). Interestingly, in the 
aforementioned study by Segura et al., high miR-193b was associated with longer 
post-recurrence survival. In another two studies from Chen et al., miR-193 was found to act as 
a tumor suppressor and down-regulate CCND1 and MCL1 (132, 133). Between these studies, 
there seem to be discrepancies which may be solved by further studies with independent 
cohort of samples and identification of more miR-193b targets. 
1.3 Aim of this study 
One of the interesting and yet unsolved questions in the melanoma research field is why 
melanomas progress extremely fast once they have become metastatic. In our database, we 
observed that patients with advanced melanoma often have very poor prognosis. However, 
survival times of individual patients can vary significantly, from months to years, indicating that 
the aggressiveness of melanoma in these patients may be different. Enormous efforts have 
been made to understand the molecular mechanisms involved in the aggressiveness of 
metastatic melanoma. As summarized above, miRNAs have recently emerged as key players 
in the development and progression of cancer, including melanoma.  
The aim of this study was to: 
1. identify miRNAs that may account for the aggressiveness of melanoma by miRNA 
expression profiling of melanoma cell lines derived from metastatic melanoma patients 
with long or short survival times, respectively; 
2. seek for novel miRNA targets and to explore the function of the identified miRNAs in 
melanoma. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Cells 
HEK293T ATCC, Rockville, MD 
Sk-Mel-23 Memorial Sloan-Kettering Cancer Center, 
New York, NY 
Other Melanoma cell lines (Table 1) Clinical Cooperation Unit of 
Dermato-Oncology, DKFZ, Heidelberg, 
Germany  
NHEMs from adult skin PromoCell, Heidelberg, Germany 
NHEMs from juvenile foreskin 
Juvenile foreskin 
Isolated from juvenile foreskin 
Department of Surgery, University Hospital 
Heidelberg, Heidelberg, Germany 
TOP10 E. coli competent cells Invitrogen, Carlsbad, CA 
Table 1  Information of melanoma cell lines 
Sample 
Age 
(yr) 
Sex 
Stage at 
biopsy 
Survivala 
(mo) 
Group 
1st round 
miRNA chipb 
1st round 
qPCR 
2nd round 
miRNA chip 
2nd round 
qPCR 
Gene 
Chipc 
Ma-Mel-12 48.5 M IV  5.9 Long   x x MA 
Ma-Mel-26a 73.0 M III  3.3 Long x, P x x x MA 
Ma-Mel-36 27.2 M IV  6.0 Long x, P x x x MA 
Ma-Mel-51 47.7 M IV  3.1 Long x, P x x x HD 
Ma-Mel-57 78.2 M IV  5.0 Long x, P x x x HD 
Ma-Mel-59a 52.3 M IV  6.7 Long x, P x x x MA 
Ma-Mel-71 45.6 M IV  5.0 Long x, P x x x MA 
Ma-Mel-73a 74.6 M IV  3.9 Long x, P x x x MA 
Ma-Mel-75 59.8 M III  6.6 Long x, P x x x MA 
Ma-Mel-134 67.7 M III  4.7 Long x, P x x x HD 
Ma-Mel-38 63.4 F IV  8.0 Long P x x x HD 
Ma-Mel-63a 44.2 F IV  4.7 Long P x x x MA 
Ma-Mel-66b 65.6 F IV  6.7 Long   x x MA 
Ma-Mel-76 63.4 F IV  6.7 Long P x x x MA 
Ma-Mel-80d 63.6 F IV  6.8 Long   x x HD 
Ma-Mel-101 33.6 F IV  8.4 Long P x x x HD 
Ma-Mel-103a 47.4 F IV  10.0 Long P x x x HD 
Ma-Mel-1 64.9 M IV  27.9 Short   x x HD 
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Sample 
Age 
(yr) 
Sex 
Stage at 
biopsy 
Survivala 
(mo) 
Group 
1st round 
miRNA chipb 
1st round 
qPCR 
2nd round 
miRNA chip 
2nd round 
qPCR 
Gene 
Chipc 
Ma-Mel-8a 56.3 M III  53.4 Short x, P x x x HD 
Ma-Mel-13 49.5 M IV  45.8 Short x, P x x x MA 
Ma-Mel-53 69.1 M IV  53.9 Short P x x x MA 
Ma-Mel-61a 28.7 M IV  35.6 Short x, P x x x MA 
Ma-Mel-61ed 30.5 M IV  35.6 Short   x x HD 
Ma-Mel-79b 40.4 M IV  33.8 Short x, P x x x MA 
Ma-Mel-119e 73.5 M IV  67.8 Short x, P     
Ma-Mel-122 47.5 M IV  49.5 Short P x x x HD 
Ma-Mel-5 49.4 F IV  35.1 Short P x x x HD 
Ma-Mel-19 62.3 F IV  146.7 Short P x x x HD 
Ma-Mel-20 56.0 F IV  31.8 Short P x x x HD 
Ma-Mel-35 72.4 F IV  62.0 Short P x x x MA 
Ma-Mel-37b 59.1 F IV  108.1 Short P x x x HD 
Ma-Mel-39a 57.2 F IV  38.6 Short P x x x MA 
Ma-Mel-67 51.1 F IV  40.3 Short P x x x MA 
Ma-Mel-86b 36.3 F IV  65.1 Short P x x x MA 
Ma-Mel-128a 56.3 F IV  25.4 Short P x x x HD 
a. Survival time was calculated as overall survival time after diagnosis of stage IV melanoma.  
b. Samples used in the respective experiment are indicated with “x”. Samples pooled in the 1st round miRNA chip 
analysis are indicated with “P”. 
c. Gene chip data was from our own experiment (HD) or from Prof. Dr. Schadendorf (MA) published in (134, 135). 
d. Ma-Mel-61a and -61e cell lines were derived from different metastasis of the same patient. Only Ma-Mel-61e 
was included in the subsequent t-test in order to insure independent samples. 
e. Ma-Mel-119 cell line was contaminated with fibroblasts and was excluded from further experiments.  
2.1.2 Cell culture media and supplements 
PRMI 1640 PAA Laboratories, Pasching, Austria 
Fetal Calf Serum (FCS) PAA Laboratories, Pasching, Austria 
Melanocyte Growth Medium M2 PromoCell, Heidelberg, Germany 
2.1.3 Kits 
miRNeasy Mini Kit Qiagen, Hilden, Germany 
TaqMan MicroRNA Reverse Transcription  Applied Biosystems, Foster City, CA 
TaqMan MicroRNA Assays Applied Biosystems, Foster City, CA 
TaqMan Gene Expression Assays Applied Biosystems, Foster City, CA 
TaqMan Universal PCR Master Mixture  Applied Biosystems, Foster City, CA 
Transcriptor First Strand cDNA Synthesis Roche Applied Science, Mannheim, Germany 
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Phusion High-Fidelity PCR Finnzymes, Espoo, Finland 
Rapid DNA Ligation Roche Applied Science, Mannheim, Germany 
QuikChange Lightning Site-Directed 
Mutagenesis 
Stratagene, La Jolla, CA 
Dual-Luciferase Reporter Assay System Promega, Madison, WI 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
QIAprep Spin Miniprep Kit Qiagen, Hilden, Germany 
QIAGEN Plasmid Maxi Kit Qiagen, Hilden, Germany 
ECL Plus Western Blotting Detection 
System 
GE Healthcare, Buckinghamshire 
Effectene Transfection Reagent Kit Qiagen, Hilden, Germany 
2.1.4 Microarrays 
Affymetrix HG-U133 plus 2.0 chip Affymetrix, Santa Clara, CA 
Human miRNA Expression Profiling V2 
Panel 
Illumina, San Diego, CA 
2.1.5 Enzymes 
Restriction Enzymes (EcoRI, XhoI, NotI) New England Biolabs, Beverly, MA 
Pow SuperYield DNA Ploymerase Roche Applied Science, Mannheim, Germany 
2.1.6 Plasmids 
pCMX-PL1 a gift from Dr. Armin Pscherer, Molecular 
Genetics, DKFZ, Heidelberg, Germany 
psiCHECK2 Promega, Madison, WI 
2.1.7 Oligonucleotides 
DNA primers (Table 2) Eurofins MWG GmbH, Ebersberg, 
Germany 
miRNA mimics Dharmacon, Lafayette, CO 
siRNAs Dharmacon, Lafayette, CO 
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Table 2  DNA primers for cloning 
Name Sequence (5’ – 3’) 
mir101-1-F ATTGAATTCGAGCCTTCAGAGAGAGTAATGC 
mir101-1-R CATCTCGAGTTCACCTTCTTTCTTCCTGG 
MITF-R-S ATACTCGAGCGAATCCTCCCTGCACTGC 
MITF-R-A AATGCGGCCGCATGTGAAAAACCAAATGCTTTAATG 
MITF-S1M2-F TCTCTTGCGGATGCTTGGTACTTAAATGTTAATAATAGTCACCTGC 
MITF-S1M2-R GCAGGTGACTATTATTAACATTTAAGTACCAAGCATCCGCAAGAGA 
MITF-S1M3-F GTCTCTTGCGGATGCTTGGTACACCAATGTTAATAATAGTCACCTGC 
MITF-S1M3-R GCAGGTGACTATTATTAACATTGGTGTACCAAGCATCCGCAAGAGAC 
MITF-S2M2-F 
CAAACTTGTTGAATTTATTTTTAAGAAAGAAATACTTAATTGGGAAGT
TACTGTTACTTGATAACAATG 
MITF-S2M2-R 
CATTGTTATCAAGTAACAGTAACTTCCCAATTAAGTATTTCTTTCTTAA
AAATAAATTCAACAAGTTTG 
MITF-S2M3-F 
TCAGCAAACTTGTTGAATTTATTTTTAAGAAAGAAATACACAATTGGG
AAGTTACTGTTACTTGATAAC 
MITF-S2M3-R 
GTTATCAAGTAACAGTAACTTCCCAATTGTGTATTTCTTTCTTAAAAAT
AAATTCAACAAGTTTGCTG 
c-MET-R-A TATGCGGCCGCTTGCATCACTTTACTTTAATTGC 
c-MET-R-S ATACTCGAGTGCTAGTACTATGTCAAAGCAAC 
YB1-R-S AATCTCGAGAATGCCGGCTTACCATCTCT 
YB1-R-A ATGCGGCCGCCTTTATTAACAGGTGCTTGCAG 
ABCB5-R-S TAACTCGAGTGCTGTTGAGGTAGCACATATTT 
ABCB5-R-A TAAGCGGCCGCTGATTCTCAAGTCCCCAATCTT 
2.1.8 Antibodies 
anti- ß-actin monoclonal (#691001) MP Biomedicals, Solon, OH 
anti-MITF monoclonal (M6065) Sigma, Saint Louis, MO 
anti-c-Met monoclonal (#3127) Cell Signaling Technology, Beverly, MA 
anti-YB1 polyclonal (# 2749) Cell Signaling Technology, Beverly, MA 
anti-ABCB5 polyclonal (600-401-A77) Rockland Immunochemicals, Gilbertsville, PA 
anti-EZH2 monoclonal (#3147) Cell Signaling Technology, Beverly, MA 
anti-BCL2 monoclonal (#2870) Cell Signaling Technology, Beverly, MA 
anti-PARP polyclonal (#9542) Cell Signaling Technology, Beverly, MA 
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Goat-anti-mouse IgG-HRP (sc2005) Santa Cruz Biotechnology, Santa Cruz, CA 
Goat-anti-rabbit IgG-HRP (sc2004) Santa Cruz Biotechnology, Santa Cruz, CA 
2.1.9 Reagents 
Gene Ruler 100 bp DNA Ladder Fermentas, St Leon-Rot, Germany 
O’GeneRuler 1 kb DNA Ladder Fermentas, St Leon-Rot, Germany 
Precision Plus Protein Standards Bio-Rad, Richmond, CA 
Tryspin/EDTA 10x PAA Laboratories GmbH, Pasching, Austria 
DharmaFect Duo Reagent Dharmacon, Lafayette, CO 
DharmaFect 1 Reagent Dharmacon, Lafayette, CO 
Cell Lysis Buffer Cell Signaling Technology, Beverly, MA 
Bio-Rad Protein Assay reagent Bio-Rad, Richmond, CA 
BD Matrigel Basement Membrane Matrix BD Biosciences, Bedford, MA 
Cell Proliferation Reagent WST-1 Roche Applied Science, Mannheim, Germany 
2.1.10 Chemicals 
Tryspin/EDTA 10x PAA Laboratories GmbH, Pasching, Austria 
Phosphate Buffered Saline (PBS) Biochrom AG, Berlin, Germany  
Dimethyl sulfoxide (DMSO) Applichem, Damstadt, Germany 
Agrose Sigma, Saint Louis, MO 
Tris Base Sigma, Saint Louis, MO 
Ammonium persulfate Sigma, Saint Louis, MO 
Tetramethylethylenediamine (TEMED) Bio-Rad, Richmond, CA 
Sodium dodecyl sulfate (SDS) Sigma, Saint Louis, MO 
Glycine GERBU Biotechnik, Gaiberg, Germany 
Tween 20 GERBU Biotechnik, Gaiberg, Germany 
Non-fat milk powder Carl Roth GmbH, Karlsruhe, Germany 
Bovine Serum Albumin (BSA) Sigma, Saint Louis, MO 
Methanol Sigma, Saint Louis, MO 
Ethanol Sigma, Saint Louis, MO 
ß-Mercatoethanol Sigma, Saint Louis, MO 
Paraformaldehyde Sigma, Saint Louis, MO 
Crystal violet Sigma, Saint Louis, MO 
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HGF Sigma, Saint Louis, MO 
Tryptone Sigma, Saint Louis, MO 
Yeast extrac GERBU Biotechnik, Gaiberg, Germany 
Sodium chloride (NaCl) Sigma, Saint Louis, MO 
Arga Sigma, Saint Louis, MO 
2.1.11 Consumables 
Pipette tip (10, 20, 100, 200, 1000 μl) Starlab, Milton Keynes, United Kingdom 
Combitip (2.5, 5 mL) Eppendorf, Hamburg, Germany 
Serological Pipette (5, 10, 25 mL) Greiner, Frickenhausen, Germany 
Safe-Lock tube (0.5 mL, 1.5 mL) Eppendorf, Hamburg, Germany 
PCR strip tube Greiner, Frickenhausen, Germany 
MicroAmp Optical 96-Well Plate Applied Biosystems, Foster City, CA 
MicroAmp Optical Adhesive Film Applied Biosystems, Foster City, CA 
Falcon Round-Bottom Tube (14 mL) BD Biosciences, Bedford, MA 
Centrifuge tube (15 mL, 50 mL) Greiner, Frickenhausen, Germany 
tissue culture flask (75 cm2) TPP, Trasadingen, Switzerland 
Cell Culture Test Plate                  
(flat bottom, 12-, 24-, and 96-well) 
TPP, Trasadingen, Switzerland 
Petri Dishe Greiner, Frickenhausen, Germany 
Cryotube Greiner, Frickenhausen, Germany 
Culture-Insert Ibidi, Munich, Germany 
24-well Transwell plate Corning Incorporated, Lowell, MA 
Nitrocellulose Membrane  Whatman, Dassel, Germany 
2.1.12 Equipments 
ABI 7300 Real-Time PCR System Applied Biosystems, Foster City, CA 
BeadArray Reader Illumina, San Diego, CA 
Biofuge Fresco Centrifuge Heraeus, Hanau, Germany 
Biological Safety Cabinet Heraeus, Hanau, Germany 
BioPhotometer Eppendorf, Hamburg, Germany 
BioRad Mini-Gel apparatus Bio-Rad, Richmond, CA 
CASY1 Cell Counter Schaerfe System, Reutlingen, Germany 
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CO2-Incubator Binder, Tuttlingen, Germany 
Gene Array Scanner Agilent Technologies, Palo Alto, CA 
GeneChip Fluidics Station 400 Affymetrix, Santa Clara, CA 
Innova 4230 Incubator Shaker New Brunswick Scientific, Edison, NJ 
Leica DM1L Microscope Leica, Wetzlar, Germany 
Microbiological Incubator Heraeus, Hanau, Germany 
MP220 pH Meter Mettler Toledo, Columbus, OH 
Multichannel Pipette Eppendorf, Hamburg, Germany 
Multifuge X3 FR centrifuge Heraeus, Hanau, Germany 
Multipipette Eppendorf, Hamburg, Germany 
Pipetboy Brand, Wertheim, Germany 
Pipette (P2, P10, P100, P200, P100) Gilson, Bad Camberg, Germany 
Power PAC 300 power supplier Bio-Rad, Richmond, CA 
Refrigerator Liebherr, Ochsenhausen, Germany 
Roller-mixer Karl Hecht GmbH, Sondheim, Germany 
Sorvall RT7 Centrifuge Sorvall, Newton, CT 
SpectraFluor Plus fluorometer Tecan Deutschland, Crailsheim, Germany 
Thermomixer Eppendorf, Hamburg, Germany 
Veriti 96-Well Thermal Cycler Applied Biosystems, Foster City, CA 
2.1.13 Softwares 
Microsoft Office 2007 Microsoft, Redmond, USA 
ImageJ National Institutes of Health, Bethesda, MD 
Graphpad Prism 4 GraphPad Software Inc., San Diego, USA 
Leica Application Suite Leica, Wetzlar, Germany 
MultiExperiment Viewer (MeV) 4.4 Institute of Genomic Research, Rockville, MD 
Chipster CSC - IT Center for Science Ltd, Espoo, 
Finland 
Beadstudio Data Analysis Software Illumina, San Diego, CA 
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2.2 Methods 
2.2.1 Preparation of buffers and media 
50 x Tris-acetate-EDTA (TAE) buffer, pH 8.0, 1 L 
Tris base 242 g 
Acetic acid 57.1 mL 
500mM EDTA solution 100 mL 
H2O adjust the final volume to 1 L 
1 x PBS, pH 7.4, 1 L 
PBS powder 9.55 g 
H2O adjust the final volume to 1 L 
10 x SDS-PAGE Running Buffer, 1 L 
Tris base 30 g 
10 % SDS solution 100 mL 
Glycin 144 g 
H2O adjust the final volume to 1 L 
1 x Tris-buffered saline (TBS), pH 7.6, 1 L 
Tris base 2.42 g 
Acetic acid 57.1 mL 
500mM EDTA solution 100 mL 
H2O adjust the final volume to 1 L 
TBS-T 
 1 x TBS, with 0.1 % (v/v) Tween 20 
Transfer Buffer, pH 8.5, 1 L 
Tris base 3 g 
Clycin 17.5 g 
Methanol 200 mL 
H2O adjust the final volume to 1 L 
Stripping buffer, pH 6.8, 100 mL 
0.5 M Tiris-HCL (pH 6.8) 6.25 mL 
10 % (w/v) SDS solution 20 mL 
ß-Mercatoethanol 700 µL 
H2O adjust the final volume to 100 mL 
Cell freezing medium 
RPMI 1640 50 % (v/v) 
FCS 40 % (v/v) 
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DMSO 10 % (v/v) 
LB medium, pH 7.5, 1 L 
Tryptone 10 g 
Yeast extrac 5 g 
NaCl 10g 
H2O adjust the final volume to 1 L 
2.2.2 Cell culture 
Melanoma cell lines in this study were established from metastasis of patients with stage III or 
IV melanoma (Table 1). Biopsies were obtained from either a solid metastatic lesions or a 
malignant effusion after a patient’s informed consent. Melanoma cell lines and HEK293T cells 
were cultured in RPMI 1640 medium supplemented with 10% FCS. Normal Human Epidermal 
Melanocytes (NHEMs) were cultured in Melanocyte Growth Medium M2. All cell lines were 
maintained at 37 °C in a humidified 5% CO2 incubator. 
2.2.3 Total RNA isolation 
Total RNAs including small RNAs from either untransfected or transfected cells were isolated 
using miRNeasy Mini Kit according to the manufacturer’s protocol. RNA concentrations were 
determined by BioPhotometer. 
2.2.4 Microarray 
2.2.4.1 Affymetrix Gene Chip 
The whole procedure was carried out by the Core Facility of DKFZ according to the 
manufacturer’s recommendations. Briefly, double stranded cDNA synthesis was carried out 
using 3 μl total RNA and oligo-dT primer, and the cDNAs were used as templates for in vitro 
transcription of biotin-labeled RNA. The resulting cRNAs were purified, fragmentized and 
hybridized to Affymetrix HG-U133 plus 2.0 chips. Then the chips were washed and stained by 
GeneChip Fluidics Station 400, and scanned by Gene Array Scanner.  
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2.2.4.2 Illumina MicroRNA Expression Profiling Assay 
The whole procedure was carried out by the Core Facility of DKFZ according to the 
manufacturer’s recommendations. Briefly, miRNAs were polyadenylated, reverse transcribed 
into cDNAs using a biotin-labeled oligo-dT primer with a universal sequence at the 5’-end, 
attached to a solid phase, and annealed to miRNA-specific oligos which comprise three parts: 
another 5’ universal PCR priming sequence, an address sequence for capturing the product 
on the array, and the 3’ miRNA-specific sequence. The miRNA-specific oligos were extended, 
eluted and subjected to PCR fluorescent universal primers. Then, single stranded PCR 
products were prepared and hybridized to capture probes immobilized on beads in the arrays. 
In the testing (first) round, we used Human miRNA Expression Profiling V1 Panel which was 
deployed on a 96-sample Universal Array Matrix. In the 2nd round, we used Human miRNA 
Expression Profiling V2 Panel which was deployed on a 12-sample Universal BeadChip. 
Arrays were scanned by the BeadArray Reader and intensity per bead type (miRNA) was 
extracted. 
2.2.4.3 Microarray data analysis 
Affymetrix gene chip 
Raw data of 16 cell lines was from our own experiment and raw data of the other 18 cell lines 
were provided by Dr. Schadendorf (134) (Table 1). All raw data were imported into Chipster 
software (CSC - IT Center for Science Ltd, Espoo, Finland), normalized using RMA method 
(136), and reannotated using the Chip Description File (CDF) for Affymetrix HG-U133 plus 2.0 
chip (137).  
Illumina miRNA chip 
Illumina miRNA chip data was processed using Beadstudio Data Analysis Software, including 
the calculation of detection p-value and quantile normalization (138). In the first round of 
miRNA expression profiling we calculated the absolute difference between the expression 
values of the two groups divided by the sum of their standard deviations (SD_Diff), to identify 
differentially expressed miRNAs between groups. Thus, higher SD_Diff means more 
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significant difference. In the second round, quantile normalized data was imported into MeV 
4.4 software (139). miRNAs with a average signal of less than 500 were excluded. 
Hierarchical clustering based on average linkage and euclidean distance (140) was 
performed on all melanoma and melanocyte samples. T-test was used to find differentially 
expressed miRNAs between groups. Bonferroni correction of p-value (141) was performed in 
the comparison between melanoma cell lines and NHEMs to reduce the number of 
significantly differentially expressed miRNAs, but not in the comparison between long survival 
and short survival groups due to the very small number of differentially expressed miRNAs. 
2.2.5 Reverse transcription and qPCR 
For quantitation of miRNAs, reverse transcription and qPCR were performed using TaqMan 
MicroRNA Reverse Transcription Kit and TaqMan miRNA assay (Applied Biosystems, Foster 
City, CA) according to the manufacturer’s instructions. Briefly, 40 ng of total RNA was reverse 
transcribed in a 15 µL reaction using specific stem-loop primers for mature miRNAs. Two µL 
of cDNA was used for the PCR amplification in 20 µL reaction using the TaqMan Universal 
PCR Master Mixture kit. For quantitation of MITF, c-Met, YB1 and ABCB5, reverse 
transcription and PCR were carried out using Transcriptor First Strand cDNA Synthesis Kit 
and Taqman Gene Expression Assays. Briefly, 500 ng of total RNA was reverse transcribed 
in a 20 µL reaction using oligo (dT)18 as primer. cDNA was 1:5 diluted and 2 µL was used for 
the PCR in 20 µL reaction using the TaqMan Universal PCR Master Mixture kit. PCR was 
performed in triplicates. The thermal conditions are summarized in Table 3. Small nuclear 
RNA U6 (RNU6B) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as 
endogenous control for TaqMan miRNA assay and gene expression assay, respectively. 
Relative expression of the tested genes was calculated by ΔCt-method according to the 
manufacturer’s recommendation. 
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Table 3  Thermal conditions of reverse transcription and qPCR. 
miRNA Reverse Transcription 
Temperature (°C) Time (min) Cycles 
16 30 1 
42 30 1 
85 5 1 
4 ∞ 1 
Total RNA Reverse Transcription 
Temperature (°C) Time (min) Cycles 
65 10 1 
immediately on ice 5 1 
50 60 1 
85 5 1 
4 ∞ 1 
qPCR 
Temperature (°C) Time Cycles 
95 10 min 1 
95 15 sec 
40 
60 60 sec 
2.2.6 Construction of plasmids 
2.2.6.1 PCR amplification of miR-101 precursor and 3’UTRs of target 
genes 
Sequence flanking 67-bp up-stream and 56-bp down-stream of miR-101-1 precursor was 
amplified from genomic DNA of Sk-Mel-23 using a specific primer pair with restriction sites 
EcoRI (forward primer) and XhoI (reverse primer). Full-length 3’UTRs of target genes were 
amplified from genomic DNA of Sk-Mel-23 in case the 3’UTR is in one exon (MITF, c-Mer and 
ABCB5), or from mRNA of Ma-Mel-86b in case the 3’UTR spans more than one exon (YB1), 
using specific primer pairs with restriction sites XhoI (forward primer) and NotI (reverse 
primer). PCR amplicons were gel purified using QIAquick Gel Extraction Kit. 
2.2.6.2 Restriction digestion, ligation and transformation 
pCMX-PL1 plasmid and the PCR amplicon of miR-101 precursor was double-digested by 
EcoRI and XhoI and ligated to generate pCMX-PL1-mir-101 plasmid. psiCHECK2 plasmid 
and the PCR amplicons of target genes were double-digested by XhoI and NotI, and ligated to 
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generate psiCHECK2-MITF, -c-Met, -ABCB5 and -YB1. The ligation products were 
transformed into TOP10 E. coli competent cells. 
2.2.6.3 Colony PCR check and MiniPrep 
Colonies were picked up and subjected to PCR using the corresponding primer pairs. Positive 
colonies are inoculated into LB medium and plasmid was isolated using QIAprep Spin 
Miniprep Kit according to the manufacturer’s protocol. 
2.2.6.4 Sequencing and MaxiPrep 
Positive plasmids were sequenced (GATC-Biotech, Constance, Germany) and correct ones 
were purified using QIAGEN Plasmid Maxi Kit according to the manufacturer’s protocol. 
2.2.7 Transfection 
2.2.7.1 Co-transfection for dual-luciferase reporter assay 
Appropriate amount of cells were seeded into 96-well plates to achieve 40% - 60% confluency 
before transfection the next day. 100 ng of pCMX-PL1-miR-101 and 100 ng 
psiCHECK2-MITF-3’UTR were co-transfected into HEK293T or Melanoma cell lines using 
Effectene Transfection Reagent. One hundred nM of miR-137 mimic and 100 ng of reporter 
plasmid of target genes (psiCHECK2-c-Met-3’UTR, -YB1-3’UTR and -ABCB5-3’UTR) were 
co-transfected into Ma-Mel-86b cells using DharmaFect Duo reagent. 
2.2.7.2 Transfection of miRNA mimics or siRNAs for functional 
assays 
Appropriate amount of melanoma cells were seeded into 12-well, 24-well or 96-well plates to 
achieve 40% - 60% confluence before transfection the next day. 100 nM of miRIDIAN miRNA 
mimics or ON-TARGETplus SMARTpool siRNAs was transfected into the cells using 
DharmaFect 1 reagent. Medium was changed within 24 hr after transfection. 
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2.2.8 Dual-luciferase reporter assay 
Cells were cultured in 96-well plates. Twenty-four or 48 hr after transfection, medium was 
removed and 20 µL/well of Passive Lysis Buffer was added to lyse the cells followed by 
15-min incubation at room temperature. One hundred µL/well of Luciferase Assay Reagent II 
was added to quantify firefly lucifease activity and then 100 µL/well of Stop & Glo Reagent 
was added to quench firefly luciferase activity and activate Renilla lucifease. Renilla/firefly 
luciferase ratio was calculated and further normalized to the negative control.  
2.2.9 Western blot 
Cells were lysed by Cell Lysis Buffer and protein concentrations were determined by Bradford 
method using Bio-Rad Protein Assay reagent on BioPhotometer. 10 µg of total protein was 
separated by 10% or 12% polyacrylamide gel, and electro-transferred onto nitrocellulose 
membranes. After blocking with 5% of non-fat milk (BSA was used in place of non-fat milk for 
the detection of MITF) in TBS-T (Tris Buffered Saline with 0.1% Tween-20), the membranes 
were incubated with primary antibodies at 4°C overnight, followed by 3 times of 10-minute 
wash with TBS. Then, the membranes were incubated with horseradish peroxidase 
conjugated anti-mouse or anti-rabbit IgG secondary antibody at room temperature for 1 h, 
followed by 3 times of 10-minute wash with TBS. Blots were exposed to an X-ray film using 
enhanced chemiluminescence (ECL) system. Densitometric quantification of specific bands 
was performed using ImageJ software.  
2.2.10 Matrigel invasion assay 
Invasion assay was performed using Matrigel (10 μg matrigel / well) coated 24-well transwell 
plate. Briefly, cells at 72 hr post transfection were seeded into the upper insert with serum-free 
medium and the lower chamber was filled with RPMI 1640 medium containing 10% FCS or 
10 % FSC + 50 ng/mL HGF as chemo-attractant. Cells were kept at 37 °C in a humidified 5% 
CO2 incubator. After 24 hr (Ma-Mel-86b) or 48 hr (Ma-Mel-79b), the non-invading cells on the 
upper side of the insert were removed gently by cotton swab, and the invasive cells on the 
lower side of the insert, were stained with 0.1 % crystal violet and photographed under a 
microscope. Cells were counted using ImageJ software. 
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2.2.11 Wound healing migration assay 
Migration of melanoma cells was tested in wound healing assay using culture-insert. First, 
each insert was attached onto the bottom of one well in a 24-well plate. Cells at 72 hr post 
transfection were trypsinized, resuspended in RPMI 1640 medium, seeded into both 
chambers (70 μl / chamber) of a culture-insert, and incubated overnight for cell adherence. 
The culture-insert provided two cell culture reservoirs, which were separated by a ~500 µm 
thick wall. After removing the culture-inserts on the second day, a “wound” of ~500 µm was 
formed between the two cell patches. Then, 500 μl medium were added into each well. 
Photos of the remaining gaps (“wound”) were taken under microscope every 24 hr until 48 hr. 
Widths of wounds were measured at three positions for each replicate by Leica Application 
Suite.  
2.2.12 Proliferation assay 
Cell proliferation was determined by a colorimetric WST-1 assay which was based on the 
reduction of the tetrazolium salt WST-1 into formazan by cellular enzymes. Briefly, 10 µL of 
WST-1 reagent was added to the transfected cells cultured in 100 µL / well medium in a 
96-well plate and incubated for 1 h at 37 °C. The absorbance of formazan, which was in 
proportion with the number of viable cells, was measured at 450 nm (610 nm as reference). 
The assay was performed 24, 48, 72 and 96 hr after transfection.  
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3 RESULTS 
Although metastatic melanoma patients have very poor prognosis in general, the survival 
times of individual patients can be distinct, ranging from month to years, which may reflect the 
different aggressiveness of melanoma among patients. Dysregulation of miRNAs have been 
found to be involved in the development and progression of cancer, including melanoma. In 
this study, we hypothesize that there are miRNAs which may contribute to the aggressiveness 
of melanoma and thereby affect the survival of patients. We selected melanoma cell lines 
derived from the metastases of patients with either short survival (<10 months) or long 
survival (> 25 months), as well as NHEMs from healthy donors. We expected to identify 
differentially expressed miRNAs between the short and long survival groups, as well as 
between melanoma cell lines and NHEMs, using microarray miRNA profiling. Expression of 
these miRNAs was further analyzed by qPCR. Selected candidate miRNAs were then 
subjected to functional assays to test whether they could impact on the aggressiveness of 
melanoma cells. 
3.1 miRNA expression profiling for melanoma 
cell lines and NHEMs 
Microarray technology has been widely applied on miRNA expression profiling. In this study, 
we used this method to identify miRNAs that are dysregulated in melanoma and may account 
for the aggressiveness of this disease.  
3.1.1 First round 
When we started this study, the Core Facility of the DKFZ was establishing the Illumina 
miRNA expression profiling platform and we joined the testing phase using some of our RNA 
samples from melanoma cell lines. 
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3.1.1.1 miRNA expression profiling 
In the first round, we used the Illumina MicroRNA Expression Profiling Version 1 panel which 
was deployed on a 96-sample Universal Array Matrix. The 96 sample were assigned to 
several research groups and we could test only 16 samples (indicated in Table 1). As we did 
not know whether the gender of patients could have an impact on their respective miRNA 
profiles, we tested individual melanoma cell lines only from male patients with short survival 
(MS group, n=9) and long survival (ML group, n=5). We also tested 2 pooled RNA samples of 
cell lines from short survivors (P-short) and long survivors (P-long) including males and 
females. As described in the Methods session, we used SD_Diff as a criterion to judge 
whether the expression of a miRNA was different between groups or samples. A number of 
differentially expressed miRNAs were found in the comparison between MS group and ML 
group (SD_Diff > 6) or between P-short and P-long (SD_Diff > 7.5) (Table 4). Eleven miRNAs 
(mir-101, -138, -17*, -19a, -211, -301, -33a, -33b, -363, -507 and -551b) were selected to be 
further validated by qPCR.  
Table 4  Differentially expressed miRNAs in the first round miRNA expression profiling 
MS group vs. ML group 
(SD_Diff > 6) 
 
P-short vs. P-long 
(SD_Diff > 7.5) 
miRNA  FC  miRNA FC 
miR-224 -5.6  miR-551b -17.4 
miR-452 -3.4  miR-301 -6.2 
miR-31 -2.9  miR-19b -5.3 
miR-182 -2.7  miR-101 -4.4 
miR-183 -2.5  miR-214 -4.0 
miR-17* -1.9  miR-199a -3.6 
miR-33b -1.9  miR-550 -3.3 
miR-19a -1.8  miR-33a -3.2 
miR-139 1.8  miR-507 -2.8 
miR-148a 1.8  miR-138 -2.6 
miR-519e 1.9  miR-130a -2.1 
miR-135b 2.0  miR-143 -2.0 
miR-18b 2.1  miR-130b -1.5 
miR-363 2.2  miR-204 -1.4 
miR-211 2.3  miR-135b -1.0 
miR-187 3.7  miR-199a* 1.1 
   miR-374 1.1 
   miR-186 1.4 
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MS group vs. ML group 
(SD_Diff > 6) 
 
P-short vs. P-long 
(SD_Diff > 7.5) 
miRNA  FC  miRNA FC 
   miR-211 1.9 
   miR-346 1.9 
   miR-504 2.4 
   miR-421 2.4 
SD_Diff, the absolute difference between the expression values of the two groups divided by the sum of their 
standard deviations. FC, fold change; Positive value, up-regulation; Negative value, down-regulation; MS, male 
short survivors; ML, male long survivors; P-short, pooled short survivors; P-long, pooled long survivors. 
3.1.1.2 qPCR validation of selected miRNAs 
qPCR was performed to test the expression of the 11 selected miRNAs in a larger number of 
melanoma cell lines (14 from short survivors and 15 from long survivors as indicated in Table 
1). These cell lines included the 14 cell lines from male patients which were used in the 
previous miRNA microarray analysis, and more cell lines from male and female patients. 
Pearson’s correlation coefficients (r) were calculated between the miRNA microarray data and 
the qPCR data in the 14 cell lines shared in both methods (Table 5). All miRNAs showed 
positive correlations. Some miRNAs showed high correlations, such as miR-138 (r=0.81), 
miR-211 (r=0.89) and miR-551b (r=0.93); some miRNAs showed moderate correlations, such 
as miR-301 (r=0.40), miR-33a (r=0.48) and miR-363 (r=0.51). When we compared the 
expression of the 11 miRNAs in same the cell lines of the MS group (n=9) and the ML group 
(n=5) as used in the microarray analysis, we found that three miRNAs (miR-138, miR-17*, and 
miR-19a) showed significant differences between the two groups (t-test, p<0.05) (Table 5). 
However, when we compared the expression of the 11 miRNAs in a larger number of cell 
lines from short survivors (n=14) and long survivors (n=15), we could not find any of the 11 
miRNAs to be differentially expressed between the two groups (t-test, p<0.05) (Figure 5). 
Only miR-101 expression showed a trend of higher expression in long survivors compared to 
short survivors (t-test, p=0.11).  
Thus, the differentially expressed miRNAs (long survivor vs. short survivors) identified by 
microarray in a small number of cell lines from male patients could not be validated by qPCR 
in a larger number of cell lines from a combination of male and female patients. This is likely 
due to several reasons: (i) the method (SD_Diff) used to select the differentially expressed 
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miRNAs from the microarray data was not based on t-test; (ii) one of the cell lines 
(Ma-Mel-119) used in the microarray analysis turned out to be contaminated by fibroblast and 
could not represent miRNA expression profile of the original cell line; (iii) the differences found 
between small groups in the microarray analysis could be diminished when comparing larger 
groups in the qPCR analysis and thereby not significant.   
Table 5  Statistical analyses for the expression of selected miRNAs 
miRNA 
Pearson’s correlation 
coefficient between qPCR 
and microarraya 
p-value of t-test  
between  
MS and ML groupb 
mir-101 0.63 0.536 
mir-138 0.81 0.005 
mir-17* 0.62 0.023 
miR-19a 0.62 0.008 
mir-211 0.89 0.225 
mir-301 0.40 0.665 
mir-33a 0.48 0.439 
mir-33b 0.54 0.144 
mir-363 0.51 0.286 
mir-507 0.56 0.528 
mir-551b 0.93 0.181 
a. Pearson’s correlation coefficient (r) between the miRNA microarray data and the qPCR data in the 14 cell lines 
shared in both methods. 
b. T-test was performed to compare the qPCR-measured expression of the selected miRNAs in the cell lines from 
the MS group (n=9) and ML group (n=5) which were used in both microarray and qPCR analyses.  
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Figure 5  qPCR analysis of miRNA expression in melanoma cell lines. miRNA expression of 14 cell lines 
from short survivors and 15 cell lines from long survivors was determined by qPCR. Expression was normalized to 
the internal control RNU6B. The horizontal line shows the average expression level in each group. No significant 
differences were detected between groups (t-test, p<0.05).  
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3.1.2 Second round 
3.1.2.1 miRNA expression profiling 
In the second round, we performed miRNA expression profiling for a large panel of 34 
melanoma cell lines (Table 1) and 10 NHEMs. The melanoma cell lines included 17 cell lines 
from short survivors and 17 cell lines from long survivors (Ma-Mel-61a and -61e were derived 
from different metastases of one patient). The NHEMs included 2 cell lines (M9 and M11) 
from adult skin and 8 from juvenile foreskin (M2, M4, M6, M7, M8, M10, M12 and M13). The 
miRNA expression profiling was carried out using the Illumina MicroRNA Expression Profiling 
Version 2 panel which was deployed on a 12-sample Universal BeadChip.  
After data normalization, we performed hierarchical clustering for all samples which showed 
two distinct clusters (Figure 6): one consists of only melanoma cell lines, and the other one 
consists of all NHEMs and two melanoma cell lines (Ma-Mel-12 and -20). Interestingly, these 
two cell lines were both highly pigmented as most of the NHEMs were. In the melanoma 
cluster, there was a small group of 4 cell lines (Ma-Mel-51, -75, -67 and -63) which were also 
pigmented. Ma-Mel-61a and -61e were clustered close together, reflecting that they were 
from the same patient. However, separation of short survivors and long survivors was not 
seen, which indicated that there was no big difference in miRNA expression between the two 
groups. Of note, melanoma cell lines from male and female, or NHEMs from adult and 
juvenile were not separated either.  
 
Figure 6  Hierarchical clustering of all melanoma and NHEM cell lines. ML, male long survivor; FL, female 
long survivor; MS, male short survivor; FS, female short survivor; M, NHEM. 
Next, we performed t-test to compare miRNA expression between groups. In order to have 
independent samples, we excluded Ma-Mel-61a in the t-test. We found 60 differentially 
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expressed miRNAs between melanoma cell lines and NHEMs (p values were adjusted by 
Bonferroni correction, p<0.001, Figure 7), while only 17 between short survivors and long 
survivors using even less stringent criteria (unadjusted p-value, p<0.05, Figure 8). 
Hierarchical clustering using these differentially expressed miRNAs was able to separate 
melanoma cell lines and NHEMs correctly (Figure 7) but not short survivors and long 
survivors due to a few exceptions (Figure 8).  
 
Figure 7  Differentially expressed miRNAs between melanoma and NHEM cell lines. Heat map shows 
expression levels of miRNAs in the microarray analysis. Column, cell line; row, miRNA. T-test was performed to 
compare miRNA expression in melanoma and NHEM cell lines. Ma-Mel-61e was excluded in the t-test to insure 
independent samples in each group. Hierarchical clustering was performed using 60 differentially expressed 
miRNAs selected by t-test (adjusted Bonferroni correction, p<0.001).  
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Figure 8  Differentially expressed miRNAs between short survivors and long survivors. Heat map shows 
expression levels of miRNAs in the microarray analysis. Hierarchical clustering was performed using 17 
differentially expressed miRNAs selected by t-test (unadjusted, p<0.05). 
3.1.2.2 qPCR validation of the selected miRNAs 
We selected 8 miRNAs that were differentially expressed between short and long survivors for 
further validation using qPCR analysis (Table 6). However, none of the 8 miRNAs showed 
significantly different expression between the two groups (Figure 9). The expression of 
miR-525-5p and -890 were almost undetectable, and the expression of miR-1284 and -1286 
were quite low. Poor correlations between chip data and qPCR data were found (Table 6), 
with even negative correlation coefficients for 5 miRNAs (miR-423-5p, -525-5p, 1233, -1284 
and -1286). Thus, qPCR analysis failed to validate any of the selected miRNAs in the second 
round profiling. 
In summary, we selected a number of differentially expressed miRNAs between melanoma 
cell lines from short and long survivors in a first round (with small groups) and a second round 
(with large groups) microarray analyses. However, qPCR analysis could not confirm the 
differential expression observed by Illumina microarray analysis.  
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Table 6  Selected differentially expressed miRNAs between short and long survivors 
miRNA FCa r b 
miR-22 1.20 0.44 
miR-423-3p -1.15 0.33 
miR-423-5p 1.19 -0.22 
miR-525-5p 1.17 -0.15 
miR-890 1.12 0.15 
miR-1233 1.14 -0.23 
miR-1284 1.12 -0.17 
miR-1286 1.21 -0.13 
a. FC, fold change of short survivors to long survivors as analyzed by miRNA microarray. 
b. Pearson’s correlation coefficient between chip and qPCR data. 
 
Figure 9  qPCR validation of miRNA expression in melanoma cell lines. miRNA expression was determined 
in short survivors (n=17) and long survivors (n=16) using Taqman miRNA expression assay. Expression was 
normalized to the internal control RNU6B. The horizontal line shows the average expression level in each group. 
No significant differences were detected between groups (t test, p<0.05). 
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3.2 Investigation of miR-101 function in 
melanoma cells 
In the qPCR analysis for the selected miRNAs from the first round microarray, only miR-101 
showed a trend of higher expression in the long survival groups than in the short survival 
group, though the difference was not significant (p=0.11). Given that miR-101 had been 
reported to be a tumor suppressor in other types of cancer (87, 88) and that miR-101 was 
predicted to target the important transcription factor MITF, we decided to further analyze 
miR-101 expression and functions in melanoma cells. 
3.2.1 miR-101 is dysregulated in melanoma cells 
In order to test whether miR-101 is dysregulated in melanoma cells, we performed qPCR for 
the 10 NHEMs and 34 melanoma cell lines including the 29 cell lines used in the first round 
qPCR analysis and 5 additional cell lines. As shown in Figure 10A, miR-101 was significantly 
up-regulated in melanoma cell lines compared to NHEMs (p=0.010). Cell lines of long 
survivors expressed higher miR-101 than those of short survivors (p=0.028), or NHEMs 
(p=0.010). Similar results were obtained when only cell lines of stage IV patients were 
included in the comparisons (Figure 10B). 
 
Figure 10  miR-101 is dysregulated in melanoma cells. miR-101 expression was analyzed by Taqman miRNA 
assay in NHEMs and melanoma cell lines from advanced patients with long survival or short survival. miR-101 
expression were normalized to RNU6B and further calibrated to the average of all NHEMs. A. All melanoma cell 
lines were included. B. Only stage IV cell lines were included. T-test was applied to compare the differences 
between groups. As Ma-Mel-61a and -61e were from the same patient (long survivor), only Ma-Mel-61a was 
included in the t-test to insure independent samples. 
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3.2.2 MITF is a direct target of miR-101 
3.2.2.1 Target prediction 
Using TargetScan 5.0, MITF was predicted to harbor 2 putative miR-101 binding sites in the 3’ 
UTR (Figure 11). One binding site is conserved (site 1, 2934 - 2940 nt), and the other is 
poorly conserved (site 2, 1338 -1344 nt). 
5'...UCUUGCGGAUGCUUGGUACUGUA...
|| | | ..||||||||
3' AAGUCAAUAGUGUCAUGACAU
5'...UCUUGCGGAUGCUUGGUACUUAA...
|| | | ..|||||  |
3' AAGUCAAUAGUGUCAUGACAU
5'...UUUUUAAGAAAGAAAUACUGUAU...
||. | . | |||||||
3' AAGUCAAUAGUGUCAUGACAU
5'...UUUUUAAGAAAGAAAUACUUAAU...
||. | . | ||||  |
3' AAGUCAAUAGUGUCAUGACAU
5 ...UCUUGCGGAUGCUUGGUACACAA...
|| | | ..||||   |
3' AAGUCAAUAGUGUCAUGACAU
5'...UUUUUAAGAAAGAAAUACACAAU...
||. | . | |||   |
3' AAGUCAAUAGUGUCAUGACAU
MITF coding sequence
5‘ AAAAAAA
MITF 3’ UTR
Site 2
1338-1344
MITF  wt 
miR-101
MITF  2-base  mut
miR-101
MITF  3-base  mut
miR-101
Site 1
2934-2940
 
 
Figure 11  Schematic of the two predicted miR-101 binding sites in the MITF 3’UTR and site mutagenesis 
design for the reporter assay. Complementarities between miR-101 and target sites are shown. The seed 
sequence is underlined. WT, wild type; S1M2 or S1M3, site 1 with 2- or 3-base mutation; S2M2 or S2M3, site 2 
with 2- or 3-base mutation 
3.2.2.2 Construction of a miR-101 expression plasmid and a MITF 
3’UTR reporter plasmid 
The miR-101 precursor sequence was cloned into pCMX-PL1 to generate pCMX-PL1-mir-101 
expression plasmid (Figure 12). Full-length MITF 3’UTR was cloned into psiCHECK2 to 
generate psiCHECK2-MITF-3’UTR reporter plasmid (Figure 12), which was subsequentially 
used to generate the reporter plasmids containing mutations in either predicted target site 
(Figure 11).  
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Figure 12  Construction of pCMX-PL1-mir-101 and psiCHECK2-MITF-3’UTR plasmid. miR-101-1 precursor 
sequence was inserted into pCMX-PL1 plasmid between EcoRI and XhoI sites (left). MITF 3’UTR was inserted into 
psiCHECK2 plasmid between XhoI and NotI sites downstream of the Renilla luciferase gene (right). The Renilla 
luciferase (hRluc) and firefly luciferase (hluc+) serve as experimental reporter and control reporter, respectively.   
CMV-IEP, CMV immediate early promoter. Py, polyoma. enh / ori, enhancer / origin. hRluc, synthetic Renilla 
luciferase gene. hluc+, synthetic firefly luciferase gene. HSV-TK, herpes simplex virus thymidine kinase. 
3.2.2.3 Luciferase reporter assay 
Co-transfection of psiCHECK2-MITF-3’UTR and pCMX-PL1-mir-101 into HEK293T or 
melanoma cell lines (Ma-Mel-73a and -86b) strongly decreased the luciferase activities at 24 
hr and 48 hr, while co-transfection of psiCHECK2 empty (without cloned 3’UTR) and 
pCMX-PL1-mir-101 into the same cell lines did not change the luciferase activities (Figure 
13A). This indicates that miR-101 targets the 3’ UTR of MITF directly. 
To find out whether the putative binding sites are responsible for the targeting, we introduced 
a 2- or 3-base mutation in either site. As shown in Figure 13B, introduction of 2- and 3-base 
mutations in site 1 diminished the reduction of luciferase activities caused by miR-101 from 
71% to 45% and 37% (p<0.001), respectively. However, introduction of neither 2- nor 3-base 
mutation in site 2 affected the reduction of luciferase activities. Thus, only the conserved site 
(site 1) is a real target site for miR-101. Because the mutations in site 1 were unable to impair 
the targeting of MITF completely, more target sites may exist in the MITF 3’UTR.   
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Figure 13  Luciferase reporter assays validate MITF as a direct target of miR-101. A. 
psiCHECK-2-MITF-3’UTR or psiCHECK-2 empty vector was transfected with mir-101 overexpression vector 
pCMX-PL1-mir-101 or pCMX-PL1 empty vector into HEK293T, Ma-Mel-73a or Ma-Mel-86b cells. Dual-luciferase 
assay was performed at 24 hr and 48 hr after transfection. Renilla/firefly luciferase ratios were calculated, and 
further normalized to pCMX-PL1 empty which was set to 1. Three independent experiments were performed. Data 
are shown as mean ± SD. B. pCMX-PL1 empty or pCMX-PL1-mir-101 was co-transfected with 
psiCHECK-2-MITF3’UTR containing 2-base or 3-base mutation in site 1 or site 2 into Ma-Mel-86b cells. 
Dual-luciferase assay was performed at 24 hr after transfection. Renilla/firefly luciferase ratios were calculated, 
and further normalized to psiCHECK-2 empty control. Results are expressed as reductions of normalized 
luciferase activity. Three independent experiments were performed. Data are shown as mean ± SD. WT, wild type; 
S1M2 or S1M3, site 1 with 2- or 3-base mutation; S2M2 or S2M3, site 2 with 2- or 3-base mutation 
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3.2.2.4 miR-101 overexpression down-regulates MITF and EZH2 
protein in melanoma cells 
To test whether miR-101 is able to down-regulate MITF protein expression, we transfected 
Ma-Mel-79b and -86b cells with miR-101 mimic and performed Western blot analysis using 
antibody against MITF. As shown in Figure 14A, MITF protein was decreased to 62 % and 
56 % in Ma-Mel-79b and -86b cells at 72 hr after transfection of miR-101. We also tested the 
expression of EZH2, which has been reported to be an oncogene and a target of miR-101 in 
various types of cancer (87-89, 92, 93). Indeed, overexpression of miR-101 down-regulated 
EZH2 in the two tested melanoma cell lines (Figure 14A). Interestingly, overexpression of 
miR-101 in both cell lines also caused a cleavage of poly-(ADP-ribose) polymerase (PARP) 
which is one of the targets of caspase-3 and serves as a indicator for apoptosis (142).  
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Figure 14  Western blot analysis. A. Ma-Mel-79b and -86b cells were transfected with miR-101 mimic or 
negative control mimic. The protein levels of MITF, EZH2 and PARP were analyzed. The amount of cleaved PARP 
is indicative for the induction of apoptosis. B. Ma-Mel-79b and -86b cells were transfected with siRNA against 
indicated target genes or control siRNA. Seventy-two hours after transfection, protein lysates and total RNAs were 
prepared, and were subjected to Western blot with indicated antibodies. Relative densitometric quantification is 
shown below the respective bands. 
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To examine whether miR-101 could also decrease MITF mRNA, we examined MITF mRNA 
expression in the transfected cells using qPCR. Surprisingly, MITF mRNA was increased by 
48 % and 76 % upon miR-101 overexpression in Ma-Mel-79b and -86b, respectively (Figure 
15), which seems to be contradictory to our finding that miR-101 overexpression decreased 
MITF protein levels in both cell lines. It may well be that miR-101 could also down-regulate 
another target which suppressed MITF transcription or promote MITF mRNA degradation, 
leading to an increased MITF mRNA level, but the strong suppressive effect of miR-101 on 
MITF translation resulted in an down-regulation of MITF protein.  
 
Figure 15  qPCR analysis of MITF mRNA expression in transfected melanoma cells. miR-101 mimic or 
negative control mimic was transfected into Ma-Mel-79b and -86b cells. Relative expression of MITF to GAPDH 
was calculated and then normalized to the negative control. 
3.2.3 Effect of miR-101 overexpression on melanoma 
cell proliferation 
To test whether miR-101 could affect the proliferation of melanoma cells, we performed 
proliferation assays for Ma-Mel-79b and -86b cells which were transfected with miR-101 
mimic or negative control mimic (Figure 16). Twelve percent inhibition of proliferation of 
Ma-Mel-79b was observed at 48 hr after transfection, and the inhibition was much more 
pronounced at 72 hr (44%) and 96 hr (48%). However, proliferation of Ma-Mel-86b was not 
significantly affected by miR-101 overexpression.  
In order to find out whether the effect of miR-101 on proliferation could be mediated through 
its target genes, we examined cells with knockdown of MITF or EZH2 by siRNA in the 
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proliferation assay. In accordance with the miR-101 overexpression results, knockdown of 
MITF and EZH2 by siRNA started to inhibit the proliferation of Ma-Mel-79b cells at 72 hr and 
48 hr, respectively, while knockdown of MITF and EZH2 showed very little effect on the 
proliferation of Ma-Mel-86b cells (Figure 16). Hence, miR-101 might inhibit melanoma cell 
proliferation through down-regulation of MITF and EZH2, but the effects may vary in different 
cell lines. 
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Figure 16  Effect of miR-101 overexpression on melanoma cell proliferation. Ma-Mel-79b and -86b cells 
were transfected with miR-101 mimic (upper), siRNAs against target genes (lower), or the corresponding negative 
controls. Cell viability was measured by WST-1 assay every 24 hr after transfection. Results shown are 
representatives of two independent experiments. Data are presented as mean ± SD of triplicates. * p < 0.05; ** p < 
0.01. 
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3.2.4 miR-101 inhibits invasion of melanoma cells 
To test whether miR-101 could play a role on melanoma cell invasion, transwell matrigel 
invasion assay was performed on transfected melanoma cells (Figure 17). The invasion of 
Ma-Mel-79b and -86b cells was reduced to 69% and 68% upon miR-101 overexpression.  
Knockdown of EZH2 by siRNA decreased the invasion of Ma-Mel-79b and -86b cells to 63% 
and 65%. Knockdown of MITF by siRNA decreased the invasion of Ma-Mel-86 cells to 31%, 
but only 71% for Ma-Mel-79b, which might be due to that the siRNA decreased MITF to 19% 
in Ma-Mel-86b cells, but only 76% in Ma-Mel-79b cells (Figure 14B). Thus, miR-101 inhibits 
the invasion of melanoma cells, which is likely mediated by the down-regulation of miR-101 
targets MITF and EZH2. 
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Figure 17  miR-101 inhibits invasion of melanoma cells through down-regulation of MITF and EZH2. 
Ma-Mel-79b and -86b cells were transfected with miRNA mimic or siRNA as indicated in the figure, and subjected 
to matrigel invasion assays. Results shown are representatives of at least two independent experiments performed 
in duplicates. Twelve fields / condition were photographed, and invasive cells were counted and normalized to 
negative controls which were set to 100 %. Data are shown as mean ± SD of 12 fields. ** p < 0.01. Scale bar, 100 
µm. 
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3.2.5 miR-101 inhibits migration of melanoma cells 
To investigate the effect of miR-101 on cell migration, we performed wound healing migration 
assays on transfected Ma-Mel-79b and -86b cells (Figure 18).  
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Figure 18  miR-101 inhibits migration of melanoma cells. Ma-Mel-79b and Ma-Mel-86b cells were transfected 
with miR-101 mimic or negative control mimic, or with siRNAs against target genes or negative control siRNA. 
Seventy-two hours after transfection, cells were harvested, seeded into each side of an Ibidi culture-insert, and 
incubated overnight. Cells were photographed immediately after insert removal and 24 hr (Ma-Mel-86b) or 48 hr 
(Ma-Mel-79b) after removal to monitor migration. Images shown are representatives of two independent 
experiments performed in duplicates. Wound closure was measured and normalized to negative controls which 
were set to 100 %. Data are shown as mean ± SD of 4 wells from two independent experiments. * p < 0.05; ** p < 
0.01. Scale bar, 100 µm.  
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The migration of Ma-Mel-79b was reduced to 77%, 74% and 67% upon transfection of 
miR-101, MITF siRNA, and EZH2 siRNA, respectively. However, the migration of Ma-Mel-86b 
was not significantly inhibited by miR-101, though it was inhibited by knockdown of MITF and 
EZH2. Therefore, miR-101 can inhibit the migration of melanoma cells, but the effects may 
vary in different cell lines.  
In summary, we found that miR-101 was down-regulated in melanoma cell lines from short 
survivors compared to those from long survivors. We identified MITF as a novel target for 
miR-101 and confirmed the previously reported target EZH2 in melanoma cells. Functional 
assays showed that miR-101 could act as a tumor suppressor in melanoma cells by inhibiting 
proliferation, invasion and migration, which was likely mediated by the down-regulation of 
miR-101 targets MITF and EZH2.  
3.3 Investigation of miR-137 function in 
melanoma cells 
In 2008, Bemis et al. reported the first functional study on a miRNA in melanoma, which 
demonstrates that miR-137 down-regulates MITF and suggests that miR-137 may be involved 
in sun tanning response (103). Subsequent studies showed that miR-137 could act as a tumor 
suppressor in various types of cancer, such as brain tumor, colorectal cancer, head and neck 
cancer, and gastric cancer (143-146). Although an anti-cancer role of miR-137 has been 
emerging in melanoma recently (147, 148), a link between miR-137 and patient outcome is 
still lacking and additional studies are needed to elucidate the function of miR-137 in 
melanoma. Given that a single miRNA may have hundreds of targets (149), it is valuable to 
investigate whether other genes are also regulated by miR-137 and how they may contribute 
to the aggressiveness of melanoma and patient outcome. 
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3.3.1 Low miR-137 expression is associated with 
poor survival in stage IV melanoma patients 
Using Taqman miRNA assay, we analyzed miR-137 expression of 10 NHEMs and 34 
melanoma cell lines derived from metastasis of advanced melanoma patients (stage III and IV) 
with short or long survival (Table 1). Comparisons between groups (NHEMs vs. all melanoma, 
NHEMs vs. long survival, NHEMs vs. short survival, or long survival vs. short survival) did not 
show significant differences, due to one cell line (Ma-Mel-134, stage III) in the short survival 
group which showed extremely high expression and dramatically raised the average 
expressions of the corresponding groups  (Figure 19A). When excluding stage III cell lines, 
we found that miR-137 expression was significantly lower in the short survivor group than in 
the long survivor group (p = 0.031) or in the NHEM group (p = 0.028) (Figure 19B). There 
was a trend that miR-137 was down-regulated in stage IV melanoma cell lines compared to 
NHEMs, although the difference (p = 0.095) did not reach a significant level.  
 
Figure 19  Expression of miR-137 in NHEMs and melanoma cell lines. miR-137 expression was analyzed by 
Taqman miRNA assay in NHEMs and melanoma cell lines from advanced patients with long survival or short 
survival. miR-137 expression was normalized to RNU6B and further calibrated to the average of all NHEMs. A. All 
melanoma cell lines were included. B. Only stage IV cell lines were included. T-test was applied to compare the 
differences between groups. As Ma-Mel-61a and -61e were from the same patient (long survivor), only 
Ma-Mel-61a was included in the t-test to insure independent samples. * p < 0.05. 
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3.3.2 miR-137 directly targets c-Met, YB1 and ABCB5 
3.3.2.1 Target selection based on microarray data 
To look for other candidate targets of miR-137, we did correlation analysis between miR-137 
expression and mRNA expression of 17589 different genes, using available miRNA and 
mRNA microarray data from 34 melanoma cell lines. We found that miR-137 expression was 
negatively correlated with the mRNA expression of a number of genes. c-Met, YB1 and 
ABCB5 were selected as candidate targets for miR-137 in this study (Figure 20), due to their 
involvement in melanoma progression and chemo-resistance (150-152). 
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Figure 20  Expression of miR-137 and putative target genes was negatively correlated. miR-137 and target 
genes’ expression levels from 34 different cell lines were obtained from log2 transformed microarray data. 
Pearson’s correlation coefficient (r) and p values were calculated between miR-137 and target gene expression.  
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3.3.2.2 Construction of luciferase reporter plasmid for target genes 
Full-length 3’UTRs of c-Met, YB1, and ABCB5 were cloned into psiCHECK2 to generate 
psiCHECK2-c-Met/YB1/ABCB5-3’UTR reporter plasmid (Figure 21). 
 
 
 
Figure 21  Construction of dual-luciferase reporter plasmid for the 3’UTRs of target genes. The 3’UTR of 
c-Met, YB1, and ABCB5 were inserted into psiCHECK2 plasmid between XhoI and NotI sites downstream of the 
Renilla luciferase gene. The Renilla luciferase (hRluc) and firefly luciferase (hluc+) serve as experimental reporter 
and control reporter, respectively. hRluc, Synthetic Renilla luciferase gene. hluc+, Synthetic firefly luciferase gene. 
HSV-TK, herpes simplex virus thymidine kinase. 
 
3.3.2.3 Luciferase reporter assay 
To test whether miR-137 targets c-Met, YB1 and ABCB5 through their 3’ UTR, dual luciferase 
assays were performed using reporter plasmid containing the respective full length 3’ UTRs. 
Ma-Mel-86b cell line was selected for the reporter assay because of very low endogenous 
miR-137 expression. Luciferase activities were decreased by 51%, 73% and 61%, 
respectively, when Ma-Mel-86b cells were co-transfected with miR-137 and the 
corresponding reporter plasmid for c-Met, YB1 and ABCB5 (Figure 22). 
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Figure 22  Dual luciferase reporter assay for miR-137 mediated targets repression. Reporter plasmid for 
different 3’-UTR of target genes (c-Met, YB1 and ABCB5) was co-transfected with negative control mimic, or with 
miR-137 mimic into Ma-Mel-86b cells. Dual-luciferase assay was performed 48 hr after transfection. Renilla / firefly 
luciferase ratios were calculated, and further normalized to the negative control. Shown are representatives of 
three independent experiments. Data are presented as mean ± SD of triplicates. ** p < 0.01.  
 
3.3.2.4 Validation of target genes by Western blotting and qPCR 
To further evaluate whether miR-137 down-regulates c-Met, YB1 and ABCB5 at protein or 
mRNA level, or both, we performed Western blot and qPCR to detect the protein and mRNA 
expression of the three genes for miR-137 transfected Ma-Mel-79b and -86b cells. As shown 
in Figure 23 and Figure 24A, overexpression of miR-137 decreased the protein and mRNA 
expression of YB1 and ABCB5 in both cell lines compared to the negative control. miR-137 
reduced c-Met protein expression in both cell lines, though c-Met mRNA expression was 
reduced only in Ma-Mel-79b. Thus, miR-137 may down-regulate both mRNA and protein of 
c-Met, YB1 and ABCB5, but it can be cell-context dependent. 
A few target genes of miR-137 have been reported previously, such as MITF, CDK6 and 
c-terminal binding protein 1(CtBP1) in cutaneous or uveal melanoma (103, 147, 148), 
mindbomb homolog 1 (Mib1) in embryonic neurons (153), Ezh2 in adult neuronal stem cell 
(154), and cell division cycle 42 (CDC42) in colorectal cancer cell (144). In the present study, 
we also included MITF and EZH2, because MITF is an important transcriptional factor 
associated with melanoma cell growth and survival and EZH2 contributes to the development 
of many solid tumors and its expression was associated with the aggressiveness of 
cutaneous melanoma (155). Indeed, Western blot showed that both MITF and EZH2 protein 
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was decreased upon miR-137 transfection in both Ma-Mel-79b and -86b cells (Figure 23). 
Moreover, overexpression of miR-137 also down-regulated BCL2, a downstream target of 
MITF, in both cell lines (Figure 23). 
Thus, we identified three new direct targets (c-Met, YB1, and ABCB5) and confirmed two 
previously reported targets (MITF and EZH2) to be regulated by miR-137 in melanoma.  
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Figure 23  Western blot analysis. Ma-Mel-79b and -86b cells were transfected with miR-137 mimic or negative 
control mimic, or with siRNAs against indicated target genes or control siRNA. Seventy-two hours after transfection, 
protein lysates and total RNA were prepared, and were subjected to Western blot with indicated antibodies. 
Densitometric quantification is shown below the respective band. 
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Figure 24  qPCR analysis. A. mRNA levels of c-Met, YB1, ABCB5 and MITF were determined in miR-137 mimic 
or negative control mimic transfected Ma-Mel-79b and -86b cells. Relative expression of target genes to GAPDH 
was calculated and then normalized to negative controls. B. Endogenous miR-137 expression was tested in 
Ma-Mel-79b and -86b cells. miR-137 expression was normalized to RNU6B. Data is shown as mean ± SD of 
triplicates. 
 
3.3.3 miR-137 inhibits invasion of melanoma cells 
through multiple targets 
We performed transwell invasion assays to analyze the effect of miR-137 on the invasive 
behavior of two melanoma cell lines. To validate the importance of the individual miR-137 
targets, we also tested whether knockdown of the selected target genes by siRNA could 
phenocopy the effect of miR-137 overexpression on melanoma cell invasion. Figure 23 
shows that the protein levels of target genes were decreased by siRNA, except c-Met in 
Ma-Mel-86b. When FCS was used as chemo-attractant, transfection of miR-137 mimic and 
siRNAs against YB1 EZH2 and MITF significantly inhibited the invasive capacity of both 
Ma-Mel-79b and -86b cells, while transfection of siRNA against c-Met did not (Figure 25A). 
Notably, such inhibitory effect on cell invasion was much stronger in Ma-Mel-86b cells 
compared to Ma-Mel-79b cells, which might be explained by the much lower endogenous 
miR-137 level in Ma-Mel-86b cells than in Ma-Mel-79b cells (Figure 24B). When using FCS 
plus HGF as chemo-attractant, knockdown of c-Met strongly reduced the invasive activity of 
Ma-Mel-79b cells (Figure 25B). This is concordant with the notion that HGF is the only known 
endogenous ligand of c-Met (156) and most melanoma cells can produce HGF that can 
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activate c-Met in an autocrine manner (150). On the contrary, knockdown of c-Met failed to 
inhibit the invasion of Ma-Mel-86b cell (Figure 25B) probably due to the fact that the 
endogenous expression of c-Met in Ma-Mel-86b cells was very low and further reduction did 
not lead to any effect. Taken together, miR-137 suppressed melanoma cell invasion which 
could be phenocopied by knockdown of each of the target genes MITF, c-Met, YB1 and 
EZH2. 
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Figure 25  miR-137 inhibits invasion of melanoma cells through down-regulation of multiple targets. 
Ma-Mel-79b and -86b cells were transfected with miRNA mimic or siRNA as indicated in the figure, and subjected 
to matrigel invasion assays. A. FCS served as chemoattractant, and invasive cells were stained at 24 hr 
(Ma-Mel-86b) or 48 hr (Ma-Mel-79b) after seeding. B. FCS and HGF served as chemoattractant, and invasive cells 
were stained at 24 hr after seeding. Results shown are representatives of at least two independent experiments 
performed in duplicates. Twelve fields / condition were photographed, and invasive cells were counted and 
normalized to negative controls which were set to 100 %. Data are shown as mean ± SD of 12 fields. * p < 0.05; ** 
p < 0.01. Scale bar, 100 µm. 
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3.3.4 miR-137 inhibits migration of melanoma cells 
To test the effect of miR-137 on the migration of melanoma cells, we performed wound 
healing migration assay with Ma-Mel-79b and -86b cells. As shown in Figure 26, 
overexpression of miR-137 significantly reduced the migratory activities of Ma-Mel-79b and 
-86b by 36% and 75%, respectively. The migration of both cell lines was suppressed 
significantly when YB1 and EZH2 were knocked down by siRNA. Knockdown of MITF also 
inhibited the migration but the difference did not reach a significant level. However, 
knockdown of c-Met was unable to affect the migration of either cell line. Thus, miR-137 may 
inhibit melanoma cell migration likely through down-regulation of YB1, EZH2 and MITF. 
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Figure 26  miR-137 inhibits migration of melanoma cells through down-regulation of multiple targets. 
Ma-Mel-79b and Ma-Mel-86b cells were transfected with miR-137 mimic or negative control mimic, or with siRNAs 
against indicated target genes or negative control siRNA. Seventy-two hours after transfection, cells were 
harvested, seeded into each side of an Ibidi culture insert, and incubated overnight. Cells were photographed 
immediately after insert removal and 24 hr (Ma-Mel-86b) or 48 hr (Ma-Mel-79b) later. Images are representatives 
of two independent experiments performed in duplicates. Wound closure was measured and normalized to 
negative controls which were set to 100 %. Data are shown as mean ± SD of 4 wells from two independent 
experiments. * p < 0.05; ** p < 0.01. Scale bar: 100 µm. 
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3.3.5 miR-137 suppresses proliferation of melanoma 
cells 
To test whether miR-137 dysregulation may affect the proliferation of melanoma cells, we 
performed proliferation assay for Ma-Mel-79b and -86b cells that were transfected with 
miR-137 mimic or negative control mimic. The proliferation of Ma-Mel-79b and -86b cells was 
suppressed by miR-137 at 96 hr and 72 hr after transfection, respectively (Figure 27). 
Knockdown of MITF and EZH2, but not c-Met or YB1, by siRNA inhibited Ma-Mel-79b 
proliferation; knockdown of MITF, c-Met and YB1, but not EZH2 inhibited Ma-Mel-86b 
proliferation (Figure 27). Hence, down-regulation of MITF, c-Met, YB1, and EZH2 by miR-137 
may contribute to the inhibition of melanoma cell proliferation, but the impact of each target 
may vary in different cell lines. 
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Figure 27  miR-137 inhibits melanoma cell proliferation. Ma-Mel-79b and -86b cells were transfected with 
miR-137 mimic (upper), siRNAs against target genes (lower), or corresponding negative controls. Cell viability was 
measured by WST-1 assay every 24 hr until 96 hr after transfection. Results shown are representatives of two 
independent experiments. Data are presented as mean ± SD of triplicates. * p < 0.05; ** p < 0.01.  
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3.3.6 miR-137 induces apoptosis of melanoma cells 
To evaluate whether miR-137 induces apoptosis in melanoma, we performed Western blot to 
analyze the cleavage of PARP which is a marker for apoptotic cells (142). We found that the 
89 kDa cleaved PARP was strongly increased after transfection of miR-137 into both 
Ma-Mel-79b and -86b cell lines (Figure 23). Furthermore, overexpression of miR-137 caused 
a decrease of the anti-apoptotic protein BCL2 in both cell lines, probably through the 
down-regulation of MITF (Figure 23). This indicates that the intrinsic apoptosis pathway is 
activated by miR-137. 
In summary, we found that low miR-137 expression was associated with poor survival in 
stage IV melanoma patients. Three novel targets (c-Met, YB1 and ABCB5) were identified 
and validated for miR-137. Functional assays showed that overexpression of miR-137 could 
suppress melanoma cell proliferation, invasion and migration likely though the 
down-regulation of the newly identified targets c-Met and YB1, as well as the previously 
reported targets EZH2 and MITF. The individual impact of these proteins on migration and 
proliferation varied among the two cell lines tested. Moreover, overexpression of miR-137 
induced apoptosis and decreased BCL2 protein levels in melanoma cells. Thus, miR-137 
serves as a tumor suppressor in melanoma. 
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4 DISCUSSION 
4.1 Discrepancy between microarray and 
qPCR data 
In this study, we intended to screen and identify differentially expressed miRNAs between 
melanoma cell lines from long survival and short survival patients, or between melanoma cell 
lines and NHEMs, using microarray miRNA profiling, followed by Taqman qPCR validation. 
For testing purpose, we performed the first round of microarray analysis with a small number 
of melanoma cell lines including nine from short survivors and five from long survivors. The 
expression levels of a number of miRNAs were found to be different between the two groups. 
However, qPCR analysis of 11 selected miRNAs did not show significant differences between 
the two groups with a larger sample size. Only miR-101 showed a trend of higher expression 
in long survivors (p=0.10). Correlation analysis of miRNA chip and qPCR data was not 
satisfactory, with Pearson’s correlation coefficients being 0.40-0.93. In the second round of 
miRNA profiling, we included 34 melanoma cell lines and 10 NHEMs. Eight differentially 
expressed miRNAs between long and short survivors were selected and tested by qPCR. 
However, none of them showed significant differences between the two groups. Worse still, 
there was no good correlation between the microarray and qPCR data, with Pearson’s 
correlation coefficients being negative in some cases. Thus, the microarray miRNA profiling in 
the second round failed to identify differentially expressed miRNAs which were able to be 
further validated by qPCR.  
The discrepancy between microarray and qPCR data may come from the intrinsic technical 
problems in the microarrays used in our study. Although microarray technology has been 
successfully utilized to detect and quantitate gene expression, it faces unique challenges 
when dealing with miRNAs compared to their use in mRNA profiling: the short sequence of 
miRNAs limits the options for primer design; it is difficult to distinguish the mature miRNAs 
from their precursors as well as from their family members that may differ by a single 
nucleotide; mature miRNAs often have quite different melting temperatures (Tm) which make 
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it difficult to design the same hybridization condition across the entire array for hundreds of 
miRNAs (157).  
Recently, studies have been carried out to compare different miRNA microarray platforms. 
(157-159). Git et al. compared the performances of 6 miRNA microarray platforms (including 
Illumina) by analyzing three biological samples comprised of normal breast tissue, the luminal 
breast cancer cell line MCF7, and a breast progenitor cancer cell line PMC42 (157). They 
found that the overlap of differentially expressed miRNAs identified by the 6 platforms was 
very low and fold changes of differentially expressed miRNAs obtained from microarray data 
were compressed compared to those obtained from qPCR data. Pradervand et al. analyzed 
differential miRNA expression in RNA samples from human brain and heart using Agilent, 
Illumina and Affymetrix microarrays, as well as qPCR (Applied Biosystems) and deep 
sequencing (Illumina) (158). The Agilent platform showed the best correlation with qPCR 
(r=0.9) and deep sequencing (r=0.83), and also the least fold change compression. The 
Illumina platform showed good correlations with qPCR (r=0.88) and deep sequencing (r=0.8), 
but it suffered from a strong fold change compression. They found that differentially 
expressed miRNAs identified from different platforms varied a lot, and 8 out of 10 selected 
miRNAs from Agilent and Illumina microarrays showed a Ct value of ≥ 34 in qPCR. 
In our study, we also observed that 3 miRNAs (miR-890, -1284 and 1286) which showed 
moderate expression in Illumina microarray were almost undetectable in qPCR. This may be 
because the probes on the array had cross-hybridization with other miRNAs or with 
unprocessed miRNAs (pri- or pre-miRNA) instead of mature miRNAs. Both qPCR (Taqman) 
and Agilent microarray specifically detect mature miRNAs by stem-loop probes (160). Illumina 
microarray does not have a special probe design for mature miRNAs, though the vendor 
claims that the assay design might offer advantages for detecting mature miRNAs more 
effectively than pre-miRNAs (161). Of note, our microarray data showed that the expression 
of miR-423-3p was significantly higher in the long survival group than that in the short survival 
group, while miR-423-5p showed the opposite pattern. However, qPCR failed to confirm the 
differences. On the contrary, it showed a very strong positive correlation between these two 
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miRNAs (r=0.98), which may reflect the fact that they are from the same pre-miRNA and also 
indicate that the microarray data may be unreliable. 
Another possible reason for the discrepancy between microarray and qPCR data may be the 
differences in normalization methods. A crucial step of microarray data analysis is the 
normalization which helps to reduce measurement error and to remove systematic differences 
between samples that do not have real biological variations (138, 162). Various normalization 
algorithms, such as cyclic lowess (locally weighted scatterplot smoothing), contrast based 
methods, quantile normalization, scaling methods and non-linear methods, have been 
primarily developed for the analysis of large-scale mRNA microarray data (163). Several 
studies compared the performance of different methods in normalizing miRNA microarray 
data and quantile normalization turned out to be robust (138, 159, 162). In the original paper 
that introduced the Illumina miRNA microarray platform, quantile normalization was also 
chosen as a proper method for data processing (161). The quantile normalization assumes 
that the distributions of probe intensities on each array are the same (163). This is acceptable 
if there is no global difference in miRNA expression across samples like the cell lines from 
long and short survivors in our study. However, quantile normalization may not be a suitable 
method when the distributions of miRNA expression vary significantly in different samples like 
the heart and brain, or probably the melanoma cells and melanocytes in our study.  
qPCR is considered as the gold standard of DNA or RNA quantification because of its high 
specificity and sensitivity (164). In miRNA research, miRNA expression is usually validated by 
qPCR after a selection of candidates from microarray analysis. The normalization methods 
used for microarray data were not applicable for qPCR, due to limited number of testing 
miRNAs. Like conventional qPCRs for mRNA expression that use a housekeeping gene as 
reference, qPCRs for miRNA expression often use a “housekeeping small RNA” as reference 
(165). U6 snRNA and 5s rRNA are among the most commonly used small RNA references. 
We also used U6 as a reference RNA in our qPCR analysis. However, several recent studies 
have shown that expression of U6 and 5s is not always constant in different samples 
(165-167). Lim et al. suggested that a combination of three miRNAs (miR-103, miR-106b and 
miR-26b), but not U6 or 5s, was suitable for miRNA expression normalization in neuronal 
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differentiation models (166). Shen et al. reported that miR-23a and miR-191 are the optimal 
reference miRNAs for cervical tissues (167). Peltier et al. conducted a comprehensive study 
on identification of appropriate reference RNAs in a panel of 13 normal tissues and 5 pairs of 
tumor and normal adjacent tissues (165). miR-191 and miR-103 were found to be the most 
consistent in their expression across all the samples, whereas U6 and 5s were among the 
least stable ones. However, melanoma samples were not included in this study. Interestingly, 
Caramuta et al. showed that low expression of miR-191 was associated with poor survival in 
melanoma patients (131). Thus, further studies are needed to identify suitable references for 
miRNA quantitation in melanoma.  
Other sources of errors may also be implicated in our miRNA profiling experiment, such as 
differences in RNA sample preparation and performance in microarrays. Based on our results 
and the results from other groups in the same institute who used the same platform and also 
had unreliable data, it is more likely that the miRNA microarray platform used in our study did 
not provide satisfactory sensitivity and specificity in miRNA detection. 
 
4.2 Expression of miR-101 and miR137 is 
dysregulated in melanoma 
Generally, stage IV melanoma patients have very poor prognosis, with median survival of 6 - 
10 months and a five-year survival rate of less than 5 percent (168). The survivals of 
individual patients can vary from months to years, but the molecular mechanism behind is 
unknown so far. In the past decade, miRNAs have been recognized as important players in 
cancer and their expression has been associated with the development, progression and 
prognosis of different types of cancer, including melanoma. miR-101 has been found to be a 
tumor suppressor in several types of cancer (88-94) and a prognostic marker in endometrial 
serous adenocarcinomas (169) and in NSCLC (170). Since the first paper on miR-137 and its 
target MITF in melanoma was published in 2008 (103), there has been an increasing interest 
in the role of miR-137 in the development and progression of cancers. Several targets of 
miR-137 have been identified in various types of cancer, which indicate a tumor suppressive 
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function for miR-137 (143-146). However, so far there has been no published study on the 
prognostic effect of miR-101 or miR-137 in melanoma. This study is the first one to correlate 
expression of miR-101 and miR-137 with melanoma patients’ outcome. We selected two 
groups of melanoma cell lines from stage IV patient with distinct survival, and found that lower 
expression of miR-101 and miR-137 was associated with shorter survival. This is consistent 
with previous reports and our findings that miR-101 and miR-137 executed their tumor 
suppressive functions by targeting multiple oncogenes. Thus, down-regulation of miR-101 
and miR-137 may contribute to the increased aggressiveness of melanoma cells in stage IV 
patients. Further studies are warranted to validate the dysregulation of miR-101 and miR-137 
expression in a larger population of melanoma patients. 
In our study, there was a trend that miR-137 was down-regulated in stage IV melanoma 
samples compared to NHEMs, which is consistent with the notion that miR-137 is a tumor 
suppressor. In contrast, miR-101 showed an up-regulation in melanoma samples compared 
to NHEMs, which seems contradictory to its tumor suppressive effect on melanoma cell in our 
study. It is noteworthy that miR-101 expression was convergent at relatively low level in 
NHEMS but divergent in melanoma cell lines. Meanwhile, some melanoma cell lines, most of 
which were from short survivors, showed extremely low levels of miR-101. It could be possible 
that miR-101 expression was down-regulated to a very low level to facilitate tumorgenesis at 
the beginning, but during a certain period of progression, miR-101 expression was reactivated 
due to the release of such inhibition or induction from other factors. Although most studies 
reported miR-101 as a tumor suppressor, Sachdeva et al. reported that miR-101 was able to 
promote estrogen-independent growth of breast cancer cells and suppression of MAGI-2 by 
miR-101 decreased PTEN activity, leading to Akt activation (171). This indicates that miR-101 
may also have an oncogenic potential which may favor tumor growth at some point. The 
confusing expression pattern of miR-101 in our melanoma and NHEM samples may be 
clarified by the discovery of more miR-101 targets and also upstream regulators. 
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4.3 Target identification for miR-101 and 
miR-137 
To facilitate target identification for miRNAs, a number of target prediction algorithms have 
been invented so far. However, current algorithms are not satisfactory due to the fact that only 
a few principles on miRNA target recognition have been established (25). Thus, 
experimentation is crucial to identify real miRNA targets. Gene-specific experimental 
validation with reporter assays, qPCR, and Western blot are commonly used to test individual 
miRNA-mRNA targeting (34). Using TargetScan 5.0, two miR-101 target sites were predicted 
at MITF 3’ UTR, a conserved one and a poorly conserved one. The reporter assay showed 
that the conserved site, but not the poorly conserved one, was responsible for targeting. Of 
note, mutation in the conserved site could not abolish the targeting effect completely, leaving 
the possibility that there are other target sites for miR-101 in MITF 3’ UTR or even in other 
regions of the mRNA. Several algorithms including miRanda, RNAhybrid (172), and PITA, 
predicted additional target sites, which should be tested in future.  
Although miRNAs were initially reported to repress the translation of target genes without 
affecting their mRNA level (173), subsequent studies showed that they may also induce 
mRNA degradation, making global mRNA profiling data useful for screening miRNA targets 
(41, 42, 174). In the present study, a negative correlation between numerous mRNAs and 
miR-137 has been found. Notably, MITF and its downstream targets, such as SILV, CDK2, 
GPR143, MLANA, DCT and TRY (175), were among the most significantly down-regulated 
genes, which was concordant with the previous report that MITF is a direct target of miR-137 
(103). We selected c-Met, YB1 and ABCB5 as candidate targets of miR-137, because they 
are involved in the malignancy of melanoma and have not been reported to be direct targets 
of miR-137 so far. We did target site prediction for miR-137 in the 3’ UTRs of the selected 
candidates using 4 different algorithms (TargetScan, PicTar, Miranda, and RNAhybrid). YB1 
was predicted by all four algorithms; c-Met was predicted by Miranda and RNAhybrid; ABCB5 
was only predicted by RNAhybrid. Our luciferase reporter assays showed direct interactions 
between miR-137 and all three candidates. Furthermore, mRNA and protein down-regulation 
upon miR-137 overexpression in two melanoma cell lines was confirmed by qPCR and 
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Western blot, except that mRNA of c-Met was not decreased in Ma-Mel-86b cells, indicating 
that translational repression rather than mRNA decay might be dominant in this cell line.  
Interestingly, several reports have shown that c-Met is regulated by MITF (176-178). A recent 
study found that transfection of miR-137 into uveal melanoma cells decreased c-Met 
expression though the down-regulation of MITF (147). However, our reporter assay showed 
the possibility of direct interaction between miR-137 and c-Met 3’ UTR (Figure 22), which also 
explains why Ma-Mel-86b cells showed a slightly increased c-Met mRNA level (Figure 24A) 
but down-regulated c-Met protein level upon transfection with miR-137 (Figure 23). 
Altogether, we identified and validated one novel target (MITF) of miR-101 and three novel 
targets (c-Met, YB1 and ABCB5) of miR-137, and also confirmed the previously reported 
targets of miR-101 (EZH2) and miR-137 (MITF and EZH2). Interestingly, miR-137 and 
miR-101 share some targets, namely MITF and EZH2. 
4.4 Functional impact of miR-101 and miR-137 
through their target genes in melanoma 
4.4.1 miR-101 and its target genes 
The present study identified and validated MITF as a novel target for miR-101. In melanocytes, 
MITF is the master regulator of melanocytic differentiation, expression of melanogenic 
proteins, and cell cycle arrest (17, 179). Although there is little doubt of its crucial role in 
melanoma biology, the function of MITF is still controversial. It has been reported that MITF is 
a lineage-specific oncogene in melanoma (180) and is critical in melanoma cell proliferation 
and survival (17, 179). However, studies also showed that MITF could be down-regulated in 
advanced melanoma and could suppress melanoma cell proliferation (115, 181, 182). Hoek et 
al. identified two distinct transcriptional signatures (proliferative and invasive) in melanoma 
cell lines (134), and they have proposed that melanoma cells can switch between proliferative 
and invasive states in vivo, which is likely regulated by local microenvironmental conditions 
such as hypoxia and inflammation (179). MITF along with other melanocytic genes (e.g. TYR, 
MLANA, and DCT) were up-regulated in cell lines assigned to the proliferative signature (134). 
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Gray-Schopfer et al. propose that MITF has distinct functions in melanocytic cells at different 
expression levels and thereby its protein levels must be carefully controlled. High levels of 
MITF may promote cell cycle arrest and differentiation, while very low levels may cause cell 
cycle arrest and apoptosis. 
In our study, the proliferation of Ma-Mel-79b cells was significantly suppressed upon miR-101 
overexpression, which could be phenocopied by siRNA knockdown of MITF. However, 
overexpression of miR-101 in Ma-Mel-86b cells did not inhibit the proliferation and knockdown 
of MITF decreased the proliferation only at 96 hr post transfection. Of note, in Ma-Mel-86b 
cells, there seemed to be a slight increase of proliferation at 48, 72 and 96 hr post transfection 
of miR-101; and there was also a slight increase of proliferation at 24 hr post transfection of 
MITF siRNA, but steady decrease at 48, 72 and 96 hr (Figure 16). Since MITF expression in 
Ma-Mel-86b cells is very high, the above observation may indicate that the moderate 
down-regulation of MITF protein level by miR-101 overexpression might slightly favor the 
proliferation of Ma-Mel-86b cells. In case of knockdown of MITF by siRNA, cell proliferation 
might be favored by the moderate reduction of MITF protein at early time, but might be 
inhibited due to a dramatic decrease of MITF protein at later time.  
A few studies showed that decreased expression of MITF could increase the invasion of 
melanoma cells (179, 183), which disagrees with our results. Given that MITF is a 
transcriptional factor regulating many genes (175), it may well be that knockdown of MITF 
leads to a dysregulation of downstream genes involved in invasion. c-Met could be one of 
them as it promotes cell invasion and is up-regulated by MITF (176). Another possible 
mediator could be SNAI2, which can be transcriptionally activated by MITF and can induce 
EMT-like process in melanoma through activation of ZEB1 (184, 185). Further studies are 
warranted to clarify this question. 
EZH2 is a member of the poly-comb group proteins which repress gene transcription through 
methylation of histone H3 lysine 27 (186). EZH2 was initially reported to interact with the Vav 
proto-oncogene involved in hematopoietic signal transduction (187) and recently, many 
studies demonstrated that this protein is oncogenic (188). EZH2 is involved in the regulation 
of cell cycle progression, proliferation, tumor cell invasion and metastasis (188). 
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Overexpression of EZH2 was found in different types of cancer, including prostate(189), 
breast (190), bladder(191), and gastric cancer (192). Overexpression of EZH2 is linked to 
melanoma by immunohistochemical analysis conducted in two studies which showed that 
EZH2 was up-regulated in melanoma compared to benign nevi (193) and was associated with 
cell proliferation markers and aggressiveness of melanoma (155). However, detailed 
functional studies of EZH2 in melanoma are still lacking. Recently, several groups reported 
that miR-101 could target EZH2 in a variety of cancers, leading to decrease of cell 
proliferation, invasion and tumor growth (87-91), but this targeting interaction was not tested 
in melanoma. In the present study, we confirmed that miR-101 down-regulates EZH2 protein 
expression in melanoma cells leading to suppression of cell proliferation, invasion and 
migration.  
4.4.2 miR-137 and its target genes 
In the progression of melanoma, invasion is a prerequisite for tumor metastasis (4). Notably, 
several miR-137 targets tested in our study are associated with the invasion of tumor cells. 
c-Met is overexpressed or mutationally activated in a variety of solid tumors (194). The 
majority of melanoma cells, but not melanocytes, can produce HGF that induces continuous 
activation of c-Met, leading to down-regulation of E-cadherin and invasive growth (150). YB1 
acts as a transcriptional and translational factor (195), which is up-regulated in melanoma and 
involved in proliferation, survival, invasion and chemosensitivity of melanoma cells (151). 
EZH2 as mentioned above, is involved in tumor invasion and its overexpression has been 
associated with the aggressiveness of melanoma (155, 188). Our study shows that 
overexpression of miR-137 in melanoma cells suppressed their invasive activity which could 
be phenocopied by knockdown of these targets. 
miR-137 was able to inhibit the migration and proliferation of both cell lines. This raises the 
concern that a decrease of proliferation may affect the result of a migration assay, leading to 
misinterpretation. However, three facts argue against this concern in our experiments: (i) the 
reduction of cell migration caused by miR-137 overexpression was more pronounced than 
that of cell proliferation; (ii) Ma-Mel-86b cells almost stopped proliferating 96 hr post 
transfection of miR-137, whereas they could still migrate in wound healing assay; (iii) 
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knockdown of YB1 in Ma-Mel-79b or EZH2 in Ma-Mel-86b significantly suppressed the 
migration of the respective cell line, but did not affect the proliferation.  
Malignant melanoma is notorious for its high resistance to current therapeutic drugs. One of 
the underlying mechanisms is the impairment of the apoptosis pathway (196). Melanoma cells 
are malignantly transformed melanocytes, the natural UV-protectors of the skin, which shield 
neighboring keratinocytes from radiation by transfering melanin in melanosomes to these 
cells (196). The enhanced survival feature of melanoma cells may derive from their paternal 
melanocytes and can be fostered by additional alterations acquired during tumor progression 
(196). Interestingly, several miR-137 target genes (MITF, c-Met, YB1) tested in the present 
study are associated with melanoma cell survival. MITF, the first identified target of miR-137, 
acts as a master regulator of melanocyte development and melanoma oncogene. Continued 
MITF expression is essential for melanoma cell survival (17). BCL2, a key anti-apoptotic 
factor, has been found to be a direct MITF target (180). Apoptosis induced by MITF disruption 
in melanocytes and melanoma could be partially rescued by BCL2 overexpression (180). 
Both MITF and BCL2 were found to be associated with resistance to chemotherapies against 
melanoma (180, 196, 197). Puri et al. reported that tyrosine kinase inhibitor of c-Met induced 
apoptosis in melanoma cells (198). Schittek et al. showed that increased expression of YB1 in 
melanoma stimulated proliferation and inhibited apoptosis (151). In this study, we found that 
overexpression of miR-137 in melanoma cells induced apoptosis, and down-regulated MITF, 
BCL2, c-Met and YB1, which might sensitize melanoma cells to chemotherapeutic agents.  
Another mechanism involved in chemo-resistance is the decreased intracellular drug 
accumulation partly due to the enhanced drug efflux mediated by ABC transporters (199). 
More than 40 ABC transporter proteins have been identified so far and some of them were 
found to be expressed in melanomas, including ABCA9, ABCB1, ABCB5, ABCB8, ABCC2, 
and ABCD1 (200). ABCB1 was detected at low frequencies in cutaneous melanoma, but at 
high frequencies in non-cutaneous melanomas. Overexpression of ABCB1 in human 
cutaneous melanoma cell line induced resistance to different drugs (201). Notably, ABCB1 is 
transcriptionally up-regulated by YB1 (202). ABCB5 is frequently expressed in melanoma and 
mediates doxorubicin resistance via its function as an efflux transporter (199, 200). Therefore, 
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it is worthwhile to test whether miR-137 is able to reduce the chemoresistance of melanoma 
by targeting YB1 and ABCB5 in future. 
4.5 Therapeutic potential of miRNAs 
The identification of molecular pathways involved in melanoma provides opportunities to 
develop targeted therapies for melanoma patients (2). A number of important molecules (e.g. 
RAF, RAS, BCL2, PI3K and integrins) have been selected as targets in preclinical research or 
clinical trials which showed encouraging results (203-207). As increasing evidence shows that 
miRNAs are regulators of key signaling pathways in cancer, attention has been attracted to 
the development of miRNA based therapy for cancer (208). Since miRNAs can act as either a 
tumor suppressor or an oncogene, two strategies could basically be taken in the therapeutic 
application: reintroduction of tumor suppressive miRNAs or inhibition of oncogenic miRNAs 
using antagomirs that have complementary sequences (208, 209).  
Several preclinical studies have been carried out to explore the feasibility of using miRNAs as 
therapeutic targets. Trang et al. reported that delivery of let-7 mimic through intranasal 
passage to xenograft NSCLC tumors in mouse model significantly reduces the tumor burden 
(210). In another study, intravenous and intratumoral delivery of liqid-formulated miR-34a 
mimic into xenograft NSCLC tumors in mice led to accumulation of miR-34a in the tumor 
tissue, down-regulation of the target genes (c-Met, BCL2, and CDK4), and inhibition of tumor 
growth (211). Chen et al. developed a liposome-polycation-hyaluronic acid (LPH) nanoparticle 
decorated with tumor-targeting single-chain antibody fragment (scFv) for specific delivery of 
siRNA and miRNAs (212). Using this system, they delivered a cocktail of siRNAs (against 
c-Myc, MDM2 and VEGF), miR-34a, or a combination of siRNAs and miR-34a into the lung 
metastasis of B16F10 melanoma mouse model. Their results demonstrated that targeted 
nanoparticles enhanced the uptake of siRNA and miRNA in B16F10 lung metastasis and 
inhibited tumor growth.  
Cancer is a disease associated with many signaling pathway dysregulations (213). Since a 
single miRNA can regulate expression of multiple genes and thereby affect multiple pathways, 
miRNAs could be promising therapeutic targets or agents in cancer treatment. Our studies 
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show that miR-101 and miR-137 act as tumor suppressors by affecting crucial cellular 
processes (proliferation, invasion and migration) in melanoma through targeting multiple 
genes that regulate different pathways. It would be interesting to test these two miRNAs in 
preclinical models and finally in therapeutic applications.  
4.6 Outlook 
Based on our results, the Illumina miRNA microarray platform is not reliable and other 
methods like deep-sequencing may be more suitable for high-throughput expression analysis 
of miRNAs.  
Our studies on individual miRNAs demonstrated that low expression of miR-101 or miR-137 
was associated with poor survival of stage IV melanoma patients. We have not only identified 
and validated novel targets for miR-101 (MITF) and miR-137 (c-Met, YB1 and ABCB5), but 
also confirmed previously reported targets for miR-101(EZH2) and miR-137 (MITF and EZH2) 
in melanoma cells. We showed that overexpression of miR-101 or miR-137 could inhibit 
melanoma cell invasion, migration and proliferation, which suggests a tumor suppressive role 
of miR-101 and miR-137 in melanoma. Thus, down-regulation of miR-101 and miR-137 in 
stage IV melanoma patients may increase the aggressiveness of melanoma cells and thereby 
worsen the patient outcomes.  
Further preclinical studies are needed to test whether the in vivo application of miR-101 
and/or miR-137 may be therapeutically effective by lowering the aggressiveness melanoma or 
may improve treatment for melanoma when combined with conventional therapies. 
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